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Abstract
Prenatal exposure to bisphenol A (BPA), one of the most prevalent endocrine disrupting
chemicals, is associated with lung dysfunction and diseases in later life. However, it is
unknown if this association has a fetal origin. In this thesis, a series of in vivo and in vitro
experiments were conducted to determine the effects of prenatal exposure to BPA on fetal lung
development, and define the underlying molecular mechanisms. Environmentally relevant
doses of BPA were administered to pregnant mice via diet from embryonic day (E) 7.5 to 18.5.
Fetal lungs were analyzed at E18.5 for changes in structure and expression of key molecular
markers of lung maturation. My main findings were: (a) BPA severely retards fetal lung
maturation as evidenced by diminished alveolar airspace and thickened septa, hallmarks of
lung immaturity; (b) this immaturity is characterized by aberrant alveolar epithelial type I cell
differentiation; and (c) the effects of BPA are likely mediated through the glucocorticoid
signaling pathway, because the expression of epithelial sodium channel  (ENaCγ), a wellknown glucocorticoid receptor (GR) target gene, is down-regulated in BPA-exposed fetal
lungs. Moreover, maternal administration of dexamethasone rescues the lung immaturity
phenotype. However, the precise molecular mechanisms by which BPA represses ENaCγ in
lung cells were unknown. This important question was addressed using the A549 human lung
epithelial cell line as an in vitro model system. I found that that (d) both dexamethasone and
siRNA-mediated knockdown of GR expression blocked the inhibitory effects of BPA on
ENaCγ expression, indicating that BPA suppresses ENaCγ via inhibition of GR activity. Given
that BPA is known to function as a pro-inflammatory factor via the estrogen receptor  (ER),
and a mutual antagonism exists between the pro-inflammatory transcriptional factor NF-κB
and GR, I then explored and provide evidence supporting the notion that (e) BPA acts on ERβ to activate the NF-κB signaling pathway, which in turn leads to diminished GR activity and
consequent repression of ENaCγ expression in lung cells. Taken together, these findings
demonstrate that prenatal exposure to BPA disrupts fetal lung maturation, and suggest a fetal
origin for BPA-induced lung dysfunction and diseases.
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INTRODUCTION
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1.1

Bisphenol A
An endocrine disrupting chemical (EDC) is defined by the U.S. Environmental Protection
Agency (EPA) as “an exogenous agent that interferes with the production, release,
transport, metabolism, binding action, or elimination of natural hormones in the body
responsible for the maintenance of homeostasis and the regulation of developmental
processes”1. Exposure to EDCs has been associated with a range of human diseases
including cancer, diabetes, obesity, and decreased fertility2–4. Bisphenol A (BPA), one of
the most prevalent EDCs in the environment, has gained world-wide attention due to
growing evidence of its association with adverse health effects in humans and experimental
animal models4,5. BPA is an industrial chemical used to manufacture polycarbonate
plastics, epoxy resins lining the inside of food and beverage containers, thermal print
papers and composites used in dental sealants6–8. Almost seven billion tonnes of BPA were
produced in 20139, making it one of the highest volume chemicals produced worldwide.
The pervasiveness of BPA is such that it is detected in the air, water and soil, making
human exposure to BPA unavoidable4,10. Exposure to BPA occurs through multiple routes
including inhalation, dermal absorption, and ingestion, which is the most common route of
exposure4,10. Thus, it is not surprising that over 95% of Canadians have detectable levels
of BPA in their urine11.

BPA was first synthesized in 1891 by A.P. Dianin and was investigated in the 1930s for
potential pharmaceutical use during the search for synthetic estrogens8. Although BPA has
estrogenic activity, its pharmaceutical use was abandoned when Diethylstilbestrol (DES)
was found to be a far more potent estrogen8. The commercial use of BPA developed with
the plastics industry in the 1940s and 1950s, where it was used as a building block of
polycarbonate plastics and epoxy resins8. Although BPA is a synthetic estrogen, its
endocrine disrupting effects are not limited to the estrogen system, but extend to other
endocrine systems including those mediated by glucocorticoids, androgens, thyroid
hormones, and insulin, among others8.

3

Figure 1.1: Structure of Bisphenol A8.
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1.1.1 Mechanisms of Action
ER: Since BPA was initially synthetized as a synthetic estrogen, initial studies on the
mechanisms of BPA actions focused primarily on its effects on the estrogen receptor (ER).
The ER is mainly located in the cell nucleus12,13. Once bound to estrogenic compounds, the
ER undergoes conformational changes and binds to estrogen response elements in the
promoter region of estrogen target genes, thereby activating gene transcription12,13. In
mammals, the two major ER subtypes are ERα and ERβ14. Biochemical assays have
demonstrated that BPA can bind to both ERα and ERβ, with a 10-fold higher affinity for
ERβ15. Moreover, BPA acts as an agonist on ERβ, while demonstrating both agonist and
antagonist effects on ERα16. In addition to acting via ERα and ERβ, BPA can also act on
non-classical ERs such as binding to the membrane-bound G-protein coupled receptor 30,
and the orphan nuclear receptor estrogen-related receptor γ 15,17. BPA has been classified
as a weak estrogen, binding to ERs with 1,000-10,000 fold lower affinity than estradiol15,17–
19

. This has led to the notion that BPA might be unable to create an impact in the midst of

the already strong effects of endogenous estrogens. However, Rajapakse et al. demonstrate
that the combination effect of estradiol and BPA is in fact additive18. The spare receptor
hypothesis describes how typically, a maximal biological response can be achieved by low
concentrations of a hormone, and well before receptor occupancy becomes saturated20. The
presence of these “spare receptors” provides a mechanism for why low doses of an EDC
such as BPA might exert a response, regardless of its low affinity for the receptor15. In
addition, BPA has been shown to interact with ER in a non-classical manner that is distinct
from other known groups of ER ligands15,19, leading to the induction of a unique subset of
ER-responsive genes and associated physiological responses21. Differences have also been
noted in the recruitment of transcriptional co-regulators, indicating that BPA is not merely
an estrogen mimic8.
GR: Additional endocrine related effects of BPA include potential actions on the
glucocorticoid receptor (GR)8,22,23. The GR belongs to the superfamily of nuclear
receptors24,25, acting as a steroid-hormone activated transcriptional factor, and is expressed
by almost all cell types25,26. Glucocorticoids (GC), cortisol in humans and corticosterone
in rodents, are the physiological ligands for GR25,26. GCs play a critical role in regulating
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various physiological processes such as glucose homeostasis, cell differentiation, lung
maturation, and inflammation25,26. In the absence of GCs, the inactive GR is sequestered
in the cytoplasm bound within a large multiprotein complex that includes heat shock
proteins (HSP) 90 and 7026. These proteins contribute to GR stability by ensuring proper
protein folding and conformation, maintaining the receptor in a high affinity binding state
and stabilizing the chaperone receptor complex27. When GCs bind to the GR, chaperones
are released and the receptor dimerizes and translocates to the nucleus. In the nucleus, the
GR binds to DNA promoter elements and can either activate or repress transcription of
target genes22. Recent findings indicate that BPA can directly bind to the GR as both an
agonist and antagonist, depending on the cell type22,23,28. However, the molecular
mechanism of the direct effect of BPA on the GR signaling pathway remains unclear. In
addition to the direct effects of BPA on GR, recent studies suggest that BPA may
potentially alter the GR signaling pathway through indirect mechanisms.
NF-κB: Nuclear factor- κB (NF-κB) is a widely expressed inducible transcription factor
that is of particular importance in the immune response, as it positively regulates the
expression of many genes involved in inflammatory responses29,30. NF-κB is a
heterodimer, typically consisting of p50, and a transcriptionally active p65 subunits31. It is
latently present in the cytoplasm, under tight control by its associated inhibitory protein
IκB-α, which binds to and sequesters it in the cytosol, preventing the nuclear translocation
of NF-κB and its interaction with DNA to induce gene expression29–31. Interestingly, when
different cell types were treated with BPA, a significant increase in both the expression and
activity of NF-κB was detected32–39, concomitant with a decrease in IκB-α expression32.
Recent studies suggest that BPA increased NF-κB activity through binding to, and
activating ERβ, suggesting that BPA may function as a pro-inflammatory inducer via
ERβ36,37.
Since the potential of synthetic GCs as immunosuppressive anti-inflammatory agents was
discovered, increased focus has been directed to the mechanisms by which GCs act to
suppress the NF-κB pathway31,40–42. Indeed, a mutual antagonism has been described
between GR and NF-κB, whereby NF-κB represses GR and vice versa43–46. Since BPA has
been shown to increase NF-κB activity, this provides a possible mechanism of action of
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the repressive effects of BPA on the GR signaling pathway. Additional work is required to
elucidate the molecular mechanisms of how BPA alters the GR signaling pathway, and
whether NF-κB activation is involved in this process.
Other receptors: Other endocrine-related activities of BPA include its antagonistic actions
on the androgen receptor (AR), another receptor that belongs to the superfamily of nuclear
receptors. Results of several in vitro studies have suggested that BPA may have antiandrogenic effects at multiple steps of AR activation and function47–50. This is
demonstrated through BPA inhibition of AR interaction with its coactivator, androgen
binding of AR, AR nuclear translocation, and androgen-induced AR transcriptional
activity51. Androgens are crucial for normal male sexual development and reproduction as
they stimulate masculinization of the fetus and induce male imprinting of the developing
brain52. As such, interference with androgen action during development can result in
abnormalities of the male reproductive system. BPA also has been shown to disrupt the
thyroid hormone pathway8. BPA binds to thyroid receptor (TR) and can act as an antagonist
to inhibit transcriptional activity stimulated by thyroid hormone (triiodothyronine-T3)53,54.
In addition, data from in vitro studies have demonstrated the ability of low levels of BPA
to inhibit thyroid hormone receptor-mediated gene expression by enhancing recruitment of
the nuclear receptor co-repressor (N-CoR) to the TR54. Collectively, these findings
highlight the potential for BPA to disrupt several endocrine pathways and indicate its
ability to commandeer multiple mechanisms and pathways upon exposure.
Epigenetic alterations: The epigenome is particularly susceptible to dysregulation during
embryogenesis, as DNA methylation and chromatin patterning required for normal tissue
development is programmed during early development. Accumulating evidence indicates
that developmental exposure to BPA is thought to alter the epigenome8,55. Several in vivo
studies have demonstrated changes in DNA methylation following early life exposure to
BPA55,56. For example, when exposed to BPA prenatally and during lactation, viable
yellow agouti (Avy) mice showed epigenetic alterations manifested as a shift in coat color
towards yellow55. The shift in coat color is associated with decreased DNA methylation in
9 CpG sites examined in the promoter region of the Avy gene and in additional loci55.
Effects of developmental exposure to BPA on the epigenome have also been reported in
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organs such as the forebrain56, uterus57, and prostate58, where BPA exposure resulted in
changes in DNA methylation. Taken together, these studies provide compelling evidence
that early developmental exposure to BPA can change the offspring’s phenotype by
altering the epigenome. Since numerous studies indicate that several chronic adult diseases
and disorders result from epigenetic alterations early in development, early life exposure
to BPA poses a risk to the development of chronic diseases later in life.

1.1.2 Toxicokinetics
The bioavailability of BPA, defined as the amount of parent compound reaching the
systemic circulation, and biological activity of BPA are largely dependent on the route of
exposure, which include oral ingestion, dermal contact, and inhalation20. While oral
exposure to BPA is subject to first-pass metabolism in the gut and liver, other routes of
exposure bypass these organs, leading to higher concentrations of active BPA in
circulation59. Since BPA leaches into food from plastic packaging and resin linings of food
and beverage containers, it has been generally assumed that the consumption of
contaminated food and beverages represents the major route of human exposure. However,
new sources of exposure continue to be discovered. For example, thermal receipts used for
daily transactions have been shown to contain high levels of free BPA, raising the
possibility that transdermal absorption may be a significant source of exposure60. Indeed,
a recent study found rapid transfer of free BPA (due to holding a thermal receipt for two
seconds) from the surface of thermal receipt paper to the hand, providing evidence that
exposure to free BPA through contact with thermal paper could be an important factor in
accounting for the high levels of bioactive serum BPA reported previously in human
biomonitoring studies61. BPA is also present in cigarette filters, so smoking may be another
previously unrecognized source of exposure60. Blood concentrations of bioactive BPA are
significantly higher, indicative of higher bioavailability, in rodents following subcutaneous
(SC) or intraperitoneal (IP) injections compared with oral exposure59. These findings
demonstrate the importance of the route of exposure in determining BPA potency and
explain the more detrimental effects of BPA administered via SC or IP routes even at much
lower doses.
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Since exposure to BPA is thought to occur primarily through ingestion of contaminated
water or food6,8, the toxicokinetics of orally administered BPA has been studied extensively
in rodents, non-human primates, and humans. After oral administration, BPA is absorbed
from the gastrointestinal (GI) tract where it undergoes pre-systemic Phase II metabolism
by intestinal enterocytes or by hepatocytes after transport to the liver62,63. Phase II
metabolism increases the polarity of lipophilic compounds by conjugation reactions
through the attachment of an ionized group to the compound. The resultant metabolites are
less active than the parent compound. The active form of BPA (unconjugated BPA) is
rapidly metabolized to its inactive metabolite, BPA glucuronide (BPA-GA), by uridine
diphosphate glucuronosyltransferase (UGT) enzymes that are found in the endoplasmic
reticulum of enterocytes and hepatocytes64. These enzymes, most notably UGT2B1564,
catalyze the conversion of lipophilic compounds, such as BPA, to charged, water-soluble
glucuronides6,65. Sulfonation of BPA via sulfotransferase (SULT1A1) enzymes accounts
for other minor metabolites of BPA6,65.
Previously, it has been suggested that orally ingested BPA is rapidly inactivated by UGT
enzymes in the liver. However, this postulation was based on a single study that failed to
detect unconjugated BPA in the plasma and urine of humans66. This study was
characterized by several limitations, which include a small sample size (three woman and
six men) as well as the use of a limit of quantification (LOQ; the smallest concentration of
a substance that can be reliably measured by an analytical procedure) that was more than
10 times higher than those employed in other published studies using similar techniques66.
In fact, recent studies using non-human primates63 and rodents67 demonstrate that first-pass
metabolism of BPA after oral administration, although rapid, it is not complete. For
example, the detection of free BPA in human urine samples in biomonitoring studies
indicates internal exposure to active BPA6,68. These studies suggest that a portion of
ingested BPA bypasses first-pass metabolism and/or that BPA metabolites, mainly BPAGA, are de-conjugated in the body20. Indeed, several tissues express the enzyme βglucuronidase, which has the ability to de-conjugate and re-activate conjugated BPA10,69.
For instance, studies using rodents show that conjugated BPA is de-conjugated by βglucuronidase in the lower intestine and colon10. Since β-glucuronidase is expressed in the
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digestive tract of humans, especially those of infants, it is possible that conjugated BPA
may be de-conjugated and activated during digestion70.
The kinetics of BPA metabolism are remarkably similar in humans, non-human primates,
and rodents, as demonstrated by detection of comparable levels of BPA in serum following
oral administration62. Nonetheless, a key difference amongst these species is the route of
BPA elimination63. In rodents, BPA-GA is subjected to enterohepatic recirculation and is
primarily excreted in feces, with only small amounts excreted in urine70. Enterohepatic
recirculation prolongs the elimination process, thereby increasing internal exposure to
BPA-GA. In contrast, humans and non-human primates eliminate BPA from circulation
more rapidly than rodents, with no evidence of enterohepatic recirculation, primarily
excreting BPA-GA via urine within six hours70. This species difference in the route of
elimination prompted some investigators to emphasize the importance of enterohepatic
recirculation in rodents as a critical factor resulting in higher serum levels of BPA-GA
relative to humans and non-human primates after a similar oral dose. However, Taylor et
al. reported that the increase in concentration of free BPA in the serum of mice relative to
that of primates/humans following oral exposure was not statistically significant63. Thus,
although findings from rodent studies assessing the potential risks to humans should be
interpreted with caution, they should not be discounted. The difference in the route of
elimination of BPA between rodents (primarily via the feces) and primates (primarily via
the urine) has also been incorrectly interpreted as supporting the prediction of a different
level of clearance of BPA. However, Taylor et al. clearly demonstrate that in rhesus
monkeys and mice, the rate of clearance of free BPA from serum during the 24 h after oral
BPA administration is virtually identical63. These findings are consistent with other studies
that also reported comparable pharmacokinetics of BPA between humans and rodents20,63.
As a result, regulatory agencies have deemed the rodent model as a valid predictor to assess
the potential effects of BPA in humans20.

1.1.3 Dose-Response and Low-Dose Effects
The traditional toxicological concept that “the dose makes the poison” implies that the
higher the dose of the drug/toxin, the greater the harm. It further suggests that effects that
are not observed at high doses will similarly not be observed at low doses. This model
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generates a “safe” dose by assessing different doses of a chemical until the lowest observed
adverse effect level (LOAEL) and/or the no observed adverse effect level (NOAEL) are
determined20. The discovery of EDCs challenges this model. One of the characteristics of
EDCs, similar to naturally occurring hormones, is that they produce non-monotonic dose
response curves (NMDRCs)71. Monotonic dose response curves (also known as the
threshold model) can be both linear and non-linear. In the linear model, treatment with
increasing doses of a drug has no effect until the “threshold” dose is reached, at which point
an increase in response is observed20. In the non-linear model, a response occurs even at
the lowest treatment dose, and therefore effects at high doses can be used to predict
responses at low doses20. On the other hand, in a NMDRC, an increase in the dose does not
necessarily correspond to an increase in response20,71. The dose response curve may be Ushaped with high responses at low and high levels of exposure, or as an inverted U, with
high responses at intermediate levels of exposure20. Low-dose effects of BPA that cannot
be predicted by the response seen at high doses of exposure, demonstrate that BPA
produces a NMDRC71,72. Since the actions of BPA at low doses cannot be inferred by the
presence or absence of a response of BPA at higher doses, the traditional approach of using
high dose testing to assess chemical safety at low doses is particularly problematic for BPA.
In toxicology studies, a reference dose, defined as the maximal acceptable dose of a
compound that is considered safe for human exposure, is typically calculated using the
NOAEL20. However, in the case of BPA, the reference dose for human exposure was
calculated using the LOAEL. This is because a NOAEL could not been determined, as
adverse effects of BPA were detected even at the lowest dose administered20. This further
supports the notion that exposure to BPA, even at very low doses, can have a wide range
of adverse effects in humans. This is very alarming as the scientific literature shows that
human exposure to BPA is within the range predicted to be biologically active in over 95%
of individuals sampled11. Moreover, extensive evidence from animal studies indicate that
some outcomes may not become apparent until long after BPA exposure has occurred,
especially those effects resulting from exposure during development. These developmental
effects are irreversible and can occur due to low-dose exposure during brief sensitive
periods in development, even though BPA may not be detected during the time at which
the damage or disease is expressed. Indeed, it is evident that the effects of BPA vary with

11

the dose and time of exposure. This is especially the case when exposure occurs during the
prenatal and neonatal period, the most vulnerable window of exposure as it marks the
critical period of organogenesis. As a result, exposure to BPA during perinatal
development may have permanent adverse effects on the developing fetus.
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Figure 2.2: The predicted mechanism of adverse effects on the fetus induced by maternal
BPA exposure during pregnancy. Following oral ingestion, BPA is conjugated in the liver
and released into maternal blood. BPA-GA is transferred across the placenta, by the help
of placental transporters (i.e. Oatp and Mrp transporter families) found in trophoblast cells,
into the fetus. Certain fetal organs, such as the lung, liver, and heart, have high βglucuronidase (β-Gase) activity, which de-conjugates BPA. De-conjugated BPA may
remain in the fetus because of a deficiency in fetal UGT activities. Active BPA is capable
of altering the development of target organs such as the lungs.
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1.2

BPA during Pregnancy
While exposure to EDCs following puberty is an important factor in adverse health
outcomes, the primary concern is fetal/neonatal exposure to EDCs since developing
organisms are extremely vulnerable to perturbation by chemicals with hormone-like
activity. Adverse effects from adult exposure to EDCs are usually reversible and are
therefore termed “activational” effects73. On the other hand, exposure to EDCs during
organ development, beginning in the prenatal period and continuing through puberty, may
result in persistent “organizational” effects where the affected systems are altered even in
the absence of subsequent exposure73. Furthermore, although exposure to BPA in
adulthood requires relatively large doses to induce adverse response (in the milligrams per
kilogram of body weight range), in utero exposure to much lower doses (in the nanograms
per kilogram of body weight range) can induce alterations in organs of the fetuses that are
observed later in life. As a result, adverse effects in the developing fetus may occur at
concentrations that are far below levels that would be considered harmful in adults. Since
BPA can readily cross the placenta and reach the developing fetus69, investigations of the
effects of prenatal exposure to low doses of BPA concluded that BPA can alter the
development of several organs including the brain74,75, heart76, mammary glands77–79,
ovaries80,81, uterus82, and testes83. Such defects or malformations are not usually apparent
at birth, but rather manifest as subtle functional changes (i.e. altered gene expression,
increased cell differentiation, proliferation, and apoptosis) that increase the risk of diseases
in adult life.

1.2.1 Developmental Origins of Adult Disease
The British epidemiologist David Barker hypothesized in 1990 that the interactions
between the developing fetus and the environment determine the susceptibility of that
individual to develop metabolic disease later in life84,85. Subsequent epidemiological
investigations strongly supported the Barker hypothesis, finding that adverse events in
utero (i.e. maternal hypoxia, undernutrition, infection, stress) can permanently alter
physiological processes in adult life86–88. These clinical and animal studies sought to
understand the role of the fetal environment in the long-term regulation or ‘programming’
of adult diseases87,88. Moreover, these studies attempted to elucidate the molecular
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mechanisms involved in the etiology of these diseases in adult life. An understanding of
the role of the perinatal and/or postnatal environment on long-term health can lead to the
development of targeted therapeutic intervention strategies to prevent the onset of diseases
in adulthood.
There are concrete examples of diseases that manifest in adulthood that originated from
adverse events during fetal development87,88. For instance, pregnant women who were
administered DES, a classified EDC, to reduce the risk of pregnancy complications were
unharmed by the drug. However, their daughters who were exposed in utero had
significantly increased rates of clear cell adenocarcinoma in their reproductive tissues8,89.
They also suffered structural abnormalities in the development of their reproductive tract,
infertility, and higher rates of pregnancy complications such as spontaneous abortion,
ectopic pregnancies, and pre-term delivery. Alarmingly, the sons of women who took DES
had higher rates of non-cancerous epididymal cysts than found in the general population,
and this trend continued in the sons of DES daughters90. It is apparent that the adverse
effects of EDCs on organ systems are critically dependent on the timing of exposure.
Consequently, the vulnerability of the fetus and neonate to the adverse effects of BPA has
become the focus of intensive investigations. Perinatal and/or postnatal exposure to BPA
at doses below the established LOAEL have revealed effects on behavior, reproductive
tissues, and altered glucose homeostasis in both humans and rodents8,20.

1.2.2 Fetal Exposure to BPA
Relatively high levels of active BPA have been detected in umbilical cord blood, amniotic
fluid, fetal blood, and blood of pregnant women69,91–93, indicating that BPA readily crosses
the maternal-fetal placental barrier and can act on the fetus during critical periods of
development. Indeed, studies that examined the transfer of BPA across the placenta show
that active BPA crosses the placenta bi-directionally, mainly via passive diffusion, due to
BPA’s high lipid solubility69,91,92. This finding was confirmed in rodent studies where
pregnant rats were exposed to 14C-BPA69. Following exposure, both active and conjugated
BPA were detected in placentas and fetuses. Since the placenta expresses both UGT and
SULT enzymes94, it is possible that BPA is conjugated to the inactive form before reaching
the fetus. However, in studies that explored this possibility, only negligible amounts of
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BPA were conjugated by the placenta, suggesting that the fetus is exposed to the active
form of BPA94.
Due to alterations in the drug metabolizing and transporter systems that occur during
pregnancy, the physiological state of a pregnant mother and fetus differs from that of nonpregnant individuals69. For example, the hepatic expression of the multi-drug resistance
associated protein 2 (Mrp2), which plays an important role in excreting conjugates of
lipophilic substances, is reduced during pregnancy in the rat liver95,96. This might account
for the increased concentration of BPA in maternal blood during the entire gestational
period3,69, which potentially increases the risk of transferring conjugated BPA across the
placenta97. In addition to the active form of BPA crossing the placenta through passive
diffusion, conjugated BPA can actively cross the placenta with the help of organic aniontransporting polypeptide (Oatp) and Mrp transporter family members69,96. BPA-GA is
carried from maternal blood vessels to trophoblast cells by the Oatp4a1 (influx) transporter,
and then transported to the fetus via the Mrp1 (efflux) transporter69,98,99. Since the
conjugated form of BPA is water soluble, it cannot cross the placenta once excreted in fetal
urine, thus becomes trapped in the amniotic fluid with the potential to be swallowed and
re-circulated in the fetus97. Although BPA-GA is an inactive metabolite, fetal tissues
possess the ability to de-conjugate BPA-GA to active BPA via the enzyme βglucuronidase69,97. The majority of de-conjugation occurs in the fetal liver, also a major
site of BPA accumulation. In addition, although the presence of UGT isoforms has been
observed in fetal liver, the levels are considerably below those observed in neonates and
adults70. Due to the low expression of UGT enzymes in the fetus, fetal liver microsomes
will have limited ability to detoxify BPA through glucuronidation69,70. Consequently, free
BPA may be detected in fetal circulation as a result of the high de-conjugation ability of βglucuronidase, in combination with the limited drug metabolizing system of the fetus that
further exacerbates fetal exposure to BPA.
Pharmacokinetic disposition studies, which examine the tissue distribution of BPA,
conclude that BPA is able to distribute to various organs. Interestingly, BPA accumulated
in the lung most extensively, followed by kidneys, heart, liver, and brain, when expressed
in BPA concentration terms (i.e. amount accumulated per gram organ weight)100.
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Accumulation of BPA in the lungs may have severe implications. Indeed, exposure to BPA
is associated with lung dysfunction and is associated with various lung diseases in both
animal models as well as in clinical investigations101–112. However, it remains elusive if
this association has a fetal origin.

1.3

The Lungs
The mammalian respiratory system consists of the lungs, trachea, and vasculature113. The
lungs are air-filled organs that are divided into lobes; the right lung encompasses three
lobes, while the left has two lobes to accommodate the heart. The lungs fulfill multiple
functions, of which the most critical is to facilitate gas exchange. Structurally, the lung
consists of two intertwined and highly branched tree-like tubular systems, one conducting
air and the other blood113,114. While this arrangement is highly efficient, breathing air is not
without risks, such as exposure to airborne pathogens and dehydration115. In fact,
respiratory disorders are among the most common reasons for doctor visits in industrialized
countries, where there are higher concentrations of air-borne chemicals, pollutants,
bacteria, and viruses114.

1.3.1 The Structure and Physiological Function of the Lungs
Anatomically, the respiratory system is divided into the upper and lower respiratory tracts.
Functionally, these structures make up the system's conducting portion, which consists of
the nasal cavities, nasopharynx, larynx, trachea, bronchi, bronchioles, and terminal
bronchioles; and a respiratory portion where gas exchange takes place, consisting of
respiratory bronchioles, alveolar ducts, and alveoli113,114. The conducting portion serves
two main functions: to provide a conduit through which air moves to and from the lungs
and to condition the inspired air. To ensure an uninterrupted supply of air, a combination
of cartilage, elastic and collagen fibers, and smooth muscle provides the conducting portion
with rigid structural support and the necessary flexibility and extensibility113.
Airflow into the lungs starts at the nose and mouth, and proceeds within the thoracic cavity
via the trachea, which divides into left and right main primary bronchi. Each bronchus
branches multiple times into progressively narrower and shorter bronchi which contain
cartilage and mucous secreting glands in their walls. The bronchi branch further into
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bronchioles, which are small (<2 mm diameter) thin-walled membranous airways that lack
cartilage and glands113. Both bronchi and bronchioles are lined with a ciliated
pseudostratified columnar epithelium, also known as the respiratory epithelium, where the
cilia on the ciliated columnar cells beat in a coordinated fashion to impel an overlying layer
of mucous toward the pharynx, where it is swallowed113,114,116. This system, known as the
mucociliary blanket, plays an important role in cleansing the lungs of inhaled particles and
microorganisms that deposit on the mucous lining of airways115. Goblet cells, brush cells
and other cells in the respiratory epithelium also aid in this process. Table 1.1 summarizes
each cell type and their respective functions.
Tubular branching continues further into the distal regions of the lung where the terminal
bronchioles branch into respiratory bronchioles, then alveolar ducts until millions of
individual lung units, known as alveoli, generate a very large surface area suitable for gas
exchange. The alveoli have a continuous lining of simple squamous epithelium that is
composed of connecting cells, known as alveolar epithelial cells (AECs). This epithelium
is composed of two types of AECs. Type I cells are flattened with a large surface area to
facilitate gas exchange, and cover about 95% of the alveolar surface while constituting only
40% of all epithelial cells117,118. Type II cells account for the remaining 60% of cells lining
the alveoli, but represent only 5% of the alveolar surface, because of their cuboidal
shape117,118. Type II cells produce and secrete pulmonary surfactant, composed of a
complex of phospholipids (mainly phosphatidylcholine) and several surfactant associated
proteins (SP): SP-A, SP-B, SP-C, and SP-D119,120. The hydrophobic SP-B and SP-C
proteins enhance the spreading, absorption, and stability of surfactant phospholipids118,119.
Whereas the SP-A and SP-D proteins are important factors in host defense and are less
important in the processing of surfactant118,121. Surfactant is essential in reducing surface
tension at the air-liquid interface of the alveoli and prevents alveolar collapse during
exhalation, thereby optimizing lung compliance and facilitating the work of breathing120.
Lack of pulmonary surfactant, whether caused by premature birth, lung injury, or mutations
in genes critical to surfactant production or function, causes respiratory failure119,120,122. In
addition to type I and type II cells, some resident alveolar macrophages are found within
the alveolar space, where they act as a first line of defense against pathogens115,123. Finally,
endothelial cells of the pulmonary capillaries occupy nearly 88% of the alveolar walls124.
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The close proximity of the capillary endothelial cells and the epithelial cells of the alveoli
promotes diffusion of oxygen and carbon dioxide between the vast network of alveoli and
the capillaries that envelop them.
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Table 1.1. The different lung cell types and respective functions.
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1.4

Fetal Lung Development
Lung development during gestation is divided into two phases; lung growth (structural
development) and lung maturation (functional development)116,125. Lung growth includes
the progressive branching of the airways and the development of alveolar airspaces capable
of gas exchange123,125. This phase is followed by lung maturation and the achievement of
functionality, which is primarily a biochemical process largely regulated by hormones 125.
Survival at birth depends on (1) the architecture of the peripheral pulmonary acini and the
maturation of the gas exchange region, (2) differentiation of type I cells and their close
interface with endothelial cells of the pulmonary microvasculature system, (3) synthesis
and secretion of surfactant lipids and proteins by type II cells, and (4) clearance of lung
fluids to establish ventilation116,125. Successful lung development requires the completion
of both structural and functional development phases. Incomplete development of lung
structure and/or premature birth prior to the development of the surfactant system will lead
to respiratory compromise and/or insufficiency in the newborn124.
The embryonic lung is formed by the process of branching morphogenesis generating the
conducting airways that lead to peripheral saccules from which alveoli are produced during
the perinatal and postnatal periods of lung development123. In late gestation and after birth,
septation and continued lung growth creates the extensive alveolar surfaces mediating
efficient gas exchange. Five developmental stages have been delineated in fetal lung
development, based on anatomic and histologic characteristics116,117,123,125,126. The early
embryonic and pseudoglandular stages are characterized by the conducting airways; the
later canalicular, saccular, and alveolar stages are characterized by reduction of
mesenchyme and increased vascularization to form a thin air-blood barrier. The
development of a highly branched vascular system occurs in concert with the development
of the respiratory system. Birth does not signal the end of lung development, especially in
humans, as after birth there is a continuing process of lung growth until childhood
(approximately 8 years of age)117,127.
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1.4.1 The Embryonic Stage
The first stage of mouse fetal lung development is the embryonic stage, which is
characterized by organogenesis. The respiratory system arises from the anterior foregut
endoderm, a tissue that generates multiple organs including the esophagus, thyroid, and
liver116. In the mouse, lung specification begins at embryonic day (E) 9.0 following the
expression of the transcription factor Nkx.2.1 in endodermal cells on the ventral side of the
anterior foregut116,125,126. By E9.5, evagination of these epithelial cells results in the
formation of the trachea, which completes its separation from the esophagus, splitting the
foregut into the esophagus and trachea with two lung buds, and initiating the embryonic
stage of lung development (E9.5-E12.5). The lung buds are lined with an endodermallyderived epithelium, which further differentiates into both the respiratory epithelium that
will line the airways and the specialized epithelium that will line the alveoli. The lungs are
innervated by the ectoderm, while the mesoderm supplies the pulmonary blood vessels,
smooth muscle, cartilage, and other connective tissue.

1.4.2 The Pseudoglandular Stage
The pseudoglandular stage (E12.5-E16.5 in the mouse) is characterized by branching
morphogenesis, which is essential for forming both the structural airways as well as the
terminal alveolar compartments in which gas exchange occurs116,125,126. At E12.5, the two
primary lung buds undergo a highly regulated branching process and begin to extend into
the surrounding mesenchyme. This process depends on multiple signaling pathways
present in the mesenchyme, including the Wnt, bone morphogenetic protein (Bmp), and
fibroblast growth factor (Fgf) pathways, which regulate lung specification, branching and
patterning126. For that reason, the endodermal lung buds must be exposed to the
mesenchyme in order to undergo branching morphogenesis. Additionally, the rate and
extent of branching is directly proportional to the amount of mesenchyme present at the
time. At the end of this stage, a tree-like network of airways with thousands of terminal
branches are formed and following this point, further growth occurs by elongation and
widening of existing airways only. Furthermore, towards the end of this stage proximal
progenitor cells begin to give rise to clara, ciliated, and neuroendocrine cells. Distal
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progenitor cells also begin to appear that will differentiate into the alveolar epithelial cells
at the later stages of lung development.

1.4.3 The Canalicular Stage
In the murine model, between E16.5-E17.5, lung development enters the canalicular stage,
where branching morphogenesis is marked by the narrowing of the terminal buds, while
the respiratory tree continues to expand in diameter and length. During this stage, the gas
exchanging portion of the lung is formed and vascularized. Vascularization occurs by
vasculogenesis, the development of a vascular network from endothelial precursor cells of
lung mesenchymal origin, and by angiogenesis, the sprouting of new vessels from existing
vessels. The increased number of capillaries stimulates the terminal bronchioles to divide
further into respiratory bronchioles and alveolar ducts. In the primitive alveoli, glycogen
granules, which are later converted to glucose and used as a substrate for synthesis of
surfactant phospholipids, become evident in the undifferentiated alveolar epithelial
cells126,128. Towards the end of this stage, the undifferentiated alveolar epithelial cells begin
to differentiate into the two main specialized cell types of the alveoli, the alveolar epithelial
type I and type II cells. This is an important step as it indicates that at the end of the
canalicular phase, surfactant production starts and the gas-exchange units of the lungs are
formed122. Another crucial step at this stage is the decrease in interstitial tissue, a
prerequisite for blood-gas exchange, and the growth of the capillary network in very close
proximity to the distal surface of the alveolar cells.

1.4.4 The Saccular Stage
In the saccular stage, which extends from E17.5 to postnatal day (PD) 5 in mice, a
substantial decrease in the interstitial tissue occurs, the alveolar walls thin, and the terminal
buds begin to develop small sacs, called saccules, that are precursors of the alveoli. Saccule
development results from apoptosis as well as ongoing differentiation of mesenchymal
cells. Also during this stage, the AECs become recognizable as they differentiate into
mature squamous type I and secretory rounded type II cells containing surfactant-storing
lamellar bodies. At the same time the blood vessels, which have developed in parallel with
the airways, become closely associated with the epithelium, enveloping the alveoli. This
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encircling behavior of the blood vessels is critical to the development of the alveoli and for
the subsequent gas exchange that occurs in the postnatal period. The establishment of a
comprehensive lymphatic network in the lung tissue also occurs during this stage of
development. Towards the end of this stage, the fetal lung becomes capable of supporting
air exchange, even in prematurely born human neonates. A key factor in determining the
ability of whether the newborn lung will successfully sustain gas exchange without
collapse is the maturation of the processes of surfactant synthesis and secretion.

1.4.5 The Alveolar Stage
Following birth in mice, the saccules continue to mature in the alveolar stage (PD5 to
PD30). While the saccules are lined with mature type I and type II alveolar cells, the shape
of the saccules does not achieve the mature configuration until a few weeks after birth. In
the final stages of lung development and maturation, the terminal respiratory sacs become
functioning alveoli that are connected to alveolar ducts, lined with type I cells, which are
in intimate contact to pulmonary capillaries, and contain surfactant-producing type II cells.
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Table 1.2. The five different stages of lung development in the human and mouse. Since
the stages of lung development are comparable between the human and mouse, the mouse
has been extensively used as an embryological model when studying lung development
and maturation. The use of gene knockout strains has especially made the mouse a
remarkable tool that is essential in understanding the development of various respiratory
disorders, congenital defects in human neonates, and how the disruption of hormonal (i.e.
glucocorticoids) and morphogenetic programs early in development can lead to
deficiencies that persist throughout life.
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1.4.6 Functional Maturation of the Lungs
The cells in the lungs must undergo extensive cell differentiation to form cells with distinct
structures that perform various functions in the lungs. Specific transcriptional factors,
peptide growth factor receptor-mediated signaling pathways, extracellular matrix
components, and integrin-signaling pathways interact to direct lung cell differentiation.
Nkx2.1 is a hallmark transcription factor expressed in the lung epithelium116,126. Indeed,
the earliest known step in lung development is the establishment of localized Nkx2.1
expression129. Lungs from Nkx2.1 knockout mice do not branch and exhibit decreased
expression of many crucial lung genes, including the clara cell marker (Scgb1a1) and type
II cell markers (Surfactant proteins A-B-C-D)130. During the pseudoglandular stage of lung
development, the cells in the tips of the buds constitute a pool of highly proliferative
multipotent progenitor cells. In the course of branching morphogenesis, the Nkx2.1positive endoderm begins to develop distinct cell lineages along its proximal-distal axis,
regulated by the Sox gene family of transcription factors. Sox2 expression marks the
proximal endoderm progenitor lineage131,132, whereas the combined expression of Sox9
and the transcriptional regulator Id2 marks the distal endoderm progenitor lineage133.
Importantly, these two populations have distinct fates: the proximal progenitors give rise
to airway neuroendocrine cells, clara (secretory) cells, ciliated cells, and goblet (mucosal)
cells, whereas the distal progenitors give rise to type I and type II AECs. Both Sox2 and
Sox9 are thought to be essential for the differentiation of proximal and distal progenitors
into their various progeny as a lack of Sox2/Sox9 expression leads to the loss of mature
clara, ciliated, and alveolar epithelial cells in the lungs.
Lung epithelial cells in the tips of the buds continue to divide and populate the distal tubules
throughout the canalicular and saccular stages. Importantly, at the end of the canalicular
stage, immature AECs begin to form in the alveoli. The current model of AEC
differentiation indicates that type II cells themselves act as alveolar progenitors and give
rise to type I cells during lung development116,122,126,128,134. Furthermore, investigations in
animal models show that type II cells function as progenitor cells in the alveoli and
differentiate into type I cells following lung injury135–138.
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Figure 1.3: Epithelial cell lineages in the developing lung116,126.
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1.4.7 The Impact of Abnormal Lung Development
Normal airways develop sequentially by early epithelial tube branching and later septation
of terminal air sacs in concert with the development of the pulmonary vasculature within
lung mesenchyme and in close conjunction with epithelial differentiation125. Premature
birth, intrauterine infection, genetic mutations, or hormonal insufficiency (i.e.
glucocorticoids) can disrupt these developmental processes and result in abnormal lung
structure, deficiency of gas exchange, and neonatal respiratory failure122. Clinical examples
of such disruption of normal lung growth include neonatal respiratory distress syndrome
(RDS), a common cause of morbidity and mortality associated with premature birth due to
the insufficient production of pulmonary surfactant by immature type II cells124. More
subtle non-lethal lung dysfunctions may emerge later in life such as asthmatic wheezing
and predisposition to early onset of chronic obstructive pulmonary disease (COPD)124.
Given that the correlation between impaired lung development and the risk of developing
chronic lung disease is undisputable, it is important to delineate whether developmental
exposure to environmental insults, such as BPA, contribute to lung dysfunction and
diseases in adult life.

1.5

The Importance of Glucocorticoids during Lung Development
and Maturation
Lung development is a complex maturational process that starts in the early stages of fetal
life and continues after birth. At birth, the lungs must undergo an important change, as the
fluid-filled alveoli adjust to respiratory gas exchange. Several endocrine factors,
specifically GCs, are critical in the regulation of pulmonary development and the transition
to extrauterine life120,139. Towards the end of gestation in mammals, a surge in GCs is
essential for both structural and functional lung maturation122,140,141. Perhaps the most
compelling clinical evidence for the importance of GC-induced lung maturation was the
1972 discovery by Liggins and Howie of the positive role of GCs on fetal lung maturation
in lambs139,142. They demonstrated that administration of antenatal GCs reduced both
morbidity and mortality in preterm infants at risk for respiratory distress syndrome. Since
then, antenatal GCs are routinely administered to women who are at risk of preterm
delivery to induce maturation of the fetal lungs143,144.
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GCs exert their effects by binding to and activating the GR140. Hollenberg et al. identified
that the gene structure encoding GR in humans, by alternative splicing, generates the
classic GRα prototype and a variant isoform termed GRβ145. GRα is capable of ligand
binding and resides in the cytoplasm, while GRβ does not seem to bind GCs in vivo and is
located in the nucleus146,147. The function of GRβ in fetal tissues has not been addressed,
however, it has been shown that GRβ could repress the activity of GRα and therefore may
have the ability to antagonize the function of GRα and decrease the activity of GCs147,148.
Since mice are known to be deficient in the GRβ isoform, any mention of the GR will be
in reference to the classic GRα isoform149.
Although the GR is abundantly expressed in fetal lungs, even during early gestation, the
number of receptors varies among cell types and with gestational age150,151. In human fetal
lungs, GCs are capable of binding to the GR with high affinity as early as the second month
of gestation152,153. During this time, the GR is highly expressed in the bronchial epithelium
and terminal sac canaliculi in the lungs153. In addition, the enzyme 11-beta hydroxysteroid
dehydrogenase type II (11β-HSD II), which inactivates GCs in cells154, is expressed at very
low levels, suggesting that GCs are not being metabolized to their inactive form153,155. This
results in high local concentrations of GCs in the fetal lungs and implies a critical
regulatory role for GCs in the developing lung. Indeed, maternal administration of GCs to
pregnant primates, rabbits and rodents accelerates the transition through the
pseudoglandular phase of lung development, in association with premature terminal
differentiation and secretion of surfactant, and the initiation of structural changes required
for gas exchange, most notable alveolar thinning156–158. These in vivo effects of GCs on
distal lung maturation are reflected in vitro in both explants from developing lungs and in
cultured cell models159–161. In lung explants from humans, GCs induce expression of SP-B
and SP-C mRNA159–161. In cultured type II cells, GCs induce the expression of numerous
markers of distal differentiation of the respiratory epithelium, including Nkx2.1, a
transcription factor that is implicated in directly regulating SP-C expression, and the
expression of other genes associated with a mature alveolar epithelium162. The effects of
GCs on isolated alveolar epithelial cells thus appear to be consistent with many of the
effects of GCs in vivo, supporting an epithelial cell autonomous model for the effects of
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GCs on surfactant production in which ligand-activated GR in the developing epithelium
drives distal differentiation.
The role of GCs in regulation of lung development was further investigated using
corticotrophin-releasing hormone (CRH) knockout mice163, as well as mice with mutations
in the GR gene164,165. Although CRH-null mice have normal expression of GR in their fetal
lungs, decreased levels of GC in both maternal and fetal circulation cause postnatal death
of CRH-null offspring due to acute respiratory failure163. Maternal administration of GCs
reverses the abnormal lung phenotype in CRH-null offspring, confirming the crucial role
for GC in lung development163. Similarly, in a GR-null mouse model, where GR expression
was eliminated, GR-null offspring suffered severely impaired lung maturation164,165.
Biochemical analysis of fetal lungs from GR-null mice showed a marked reduction in type
II and type I cells which indicates that receptor-mediated GC signaling is critical in
facilitating terminal alveolar differentiation. Thus, GC signaling via the GR is essential for
both structural and biochemical maturation of the fetal lungs. Indeed, in studies conducted
in lambs, rabbits, and rodents, treatment with GCs resulted in maturation of lung epithelial
cells and stimulated differentiation of type II cells156,166.
A potential mechanism underlying this effect may be GC-mediated inhibition of DNA
synthesis, as indicated by a lower rate of thymidine incorporation into DNA in the presence
of GCs167. Inhibition of DNA synthesis restricts cell proliferation, which could stimulate
cell differentiation. This effect is observed in CRH-null mice who show continued cell
division combined with delayed maturation of type II cells in their lungs163,168. Another
possible mechanism by which GCs regulate cell differentiation is via a GC-induced
increase in aminopeptidase N, a factor that regulates cell growth and differentiation 169. In
addition to cell maturation, GCs regulate structural changes in the developing lung. The
thinning of the alveolar wall during the later stages of intrauterine lung development is
critical to effective gas exchange at birth117,125. Administration of GCs cause a decrease in
interstitial tissues in the lungs with a consequent decrease in alveolar wall thickness,
facilitating gas exchange after birth170–172.
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The late gestational increase in GCs in fetal circulation coincides with important
pulmonary maturational events, such as surfactant synthesis and alveolar septal
thinning127,141. Preterm birth can precede the late gestational increase in GCs, resulting in
the failure of GC-induced lung maturation, low levels of surfactant, and subsequent
development of neonatal RDS122,124. GC administration to pregnant women at risk of
preterm delivery has been shown to result in lung maturation, as it stimulates the production
and activity of surfactant proteins and phospholipids, components of surfactant144,173.
Furthermore, GCs influence structural changes, growth factors, and lung liquid metabolism
in the developing fetal lung that facilitate survival after preterm delivery.

1.6 Relationship between BPA and Lung Diseases
The notion that early disturbances during the development of organ systems can result in
long-term consequences for the health of the individual is well-established. Numerous
animal studies demonstrate that prenatal exposure to BPA affects fetal organ development
and may account for adverse health outcomes observed later in life. The respiratory health
effects of BPA have become the recent focus of attention. Adverse effects on lung function
and associated lung diseases have been demonstrated by early life exposure to BPA in
animal models as well as in clinical investigations. In humans, exposure to BPA during
various periods of development is associated with impaired lung function101 and the
development of asthma102,103 and wheeze104 in children. Recently, high serum levels of
BPA have been linked to chronic obstructive pulmonary disease (COPD)105. In addition,
perinatal BPA exposure induces asthma in mice106–108. More importantly, recent studies
suggest that exposure to BPA exclusively during the prenatal period is sufficient to disrupt
lung function in later life. For example, prenatal, but not postnatal exposure to BPA is
associated with diminished lung function and the development of a persistent wheeze in
children109. These findings are supported by an animal study demonstrating that exposure
to BPA during gestation, but not lactation, leads to asthma in mice110. In addition, BPA
exposure during late gestation significantly increased secretory cell expression, as
indicated by increased Clara cell secretory protein and MUC5AC mRNA and protein
expression, in the proximal conducting airways in non-human primates111,112. This increase
in airway mucins is a hallmark of a number of lung diseases that may result following
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exposure to BPA. More importantly, if mucous cell abundance is increased following
exposure to BPA, this could increase airway obstruction, making lung diseases, such as
asthma, more severe. Collectively, these findings demonstrate that early life exposure to
BPA is detrimental to lung function, and suggest that BPA may alter fetal lung
development contributing to the development of lung diseases later in life. However,
evidence in support of this hypothesis is lacking, and the underlying mechanisms are still
unclear.
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2

HYPOTHESIS AND SPECIFIC AIMS

2.1 Focus of the Thesis
Increasingly, studies are linking exposure to synthetic estrogens, such as BPA, during
sensitive periods of development to the increased incidence of infertility, genital tract
abnormalities, obesity, and various cancers. Humans are inevitably exposed to BPA
through contact with numerous consumer products, including plastic wares, inner-linings
of canned food containers, and various paper products as well as contaminated water and
food1. Importantly, BPA has been shown to accumulate in human body tissues, resulting
in much higher exposure levels than previously thought2. Of particular concern is BPA
exposure during pregnancy, a critical period during which the developing fetus is especially
vulnerable to this EDC3,4. Indeed, high levels of bioactive BPA have been detected in
amniotic fluid, umbilical cord blood, fetal and maternal blood of pregnant woman5,6.
Alarmingly, recent epidemiological studies indicate that early life exposure to BPA is
associated with impaired lung function7 and the development of asthma8,9 and wheeze10 in
children. Moreover, high serum levels of BPA are associated with COPD in humans11.
Collectively, these findings demonstrate that early life exposure to BPA is detrimental to
lung health, and suggest that BPA may alter fetal lung development, consequently leading
to lung dysfunction and diseases in adult life. However, evidence in support of this
hypothesis is lacking. The overall hypothesis of this thesis is that early life exposure to
BPA impairs fetal lung development, providing a fetal origin for BPA-induced lung
diseases. The focus of the thesis is to identify whether early life exposure to BPA disrupts
fetal lung maturation, thus providing a fetal origin to BPA-induced lung diseases in adult
life. The thesis will also examine the underlying molecular mechanisms through which
BPA disrupts fetal lung maturation, providing a molecular pathway for the disruptive
effects of BPA on fetal development.
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2.2 Specific Aim 1
To determine whether prenatal exposure to environmentally relevant doses of BPA
disrupts fetal lung maturation in the mouse.
BPA is one of the most prevalent EDCs in the environment, as a result human exposure to
BPA is inevitable12,13. Of particular concern is exposure to BPA during pregnancy, a
critical period during which organs undergo growth and differentiation to form functional
organ systems3. Indeed, early life exposure to BPA has been shown to affect the
development of various fetal organs including the brain14,15, heart16, mammary gland17,18,
ovary19,20, and uterus21. Altered fetal organ development following early life exposure to
BPA may provide a fetal origin for various BPA-induced diseases in adult life.
Proper lung development and maturation during fetal life is essential for neonatal
survival22,23. Disruptions in this process result in malformation of the lung, and can result
in neonatal death, or to more subtle non-lethal lung diseases in adult life, such as asthma
and predisposition to early onset of COPD24,25. In Chapter 3, we sought to determine
whether prenatal exposure to BPA impairs fetal lung maturation. Using the mouse as an
experimental model we hypothesized that prenatal exposure to BPA may lead to impaired
fetal lung maturation in the mouse. Environmentally relevant doses of BPA were
administered to pregnant mice via maternal diet from embryonic day (E) 7.5 to E18.5, at
which point fetal lungs were analyzed for changes in structure and expression of key
molecular markers of lung maturation. Histological analysis of the fetal lungs demonstrated
diminished alveolar airspace and thickened septa, hallmarks of lung immaturity. This
immaturity is characterized by aberrant alveolar epithelial type I cell differentiation, as the
expression of the type I cell marker, but not type II cell markers, is dramatically reduced.
Collectively, these findings suggest that BPA disrupts fetal lung maturation, and suggest
that BPA-induced lung dysfunction and diseases in adult life, as reported previously in
clinical and animal studies, may have a fetal origin. Moreover, this was the first study to
demonstrate that early life exposure to BPA affects the development of the fetal lungs,
highlighting the potential impact of BPA exposure during pregnancy on the adverse health
outcomes observed later in life.
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2.3 Specific Aim 2
To determine whether maternal administration of synthetic glucocorticoids rescues
the BPA-induced fetal lung immaturity.
During late gestation, a surge in glucocorticoid levels is essential for the proper
development and maturation of the fetal lungs26. Synthetic glucocorticoids, such as
betamethasone and dexamethasone, are commonly administered to pregnant women at risk of
preterm delivery to promote fetal lung maturation in an attempt to decrease the incidence and
severity of respiratory distress syndrome26,27. Furthermore, the lung immaturity characterized
in glucocorticoid-signaling deficient (i.e., CRH-/-) fetal mice28–30, which is remarkably
similar to lung immaturity phenotype observed in BPA exposed fetal lungs, can be rescued
by maternal dexamethasone administration. As such, we sought to determine whether
maternal administration of dexamethasone can rescue the lung immaturity phenotype observed
in BPA exposed fetuses.
Therefore, we hypothesized that maternal administration of synthetic glucocorticoids
rescues the BPA-induced fetal lung immaturity. To address this hypothesis, BPA-exposed
pregnant mice were administered two courses of dexamethasone injections at E16.5 and
E17.5, respectively. We describe in Chapter 3 that maternal dexamethasone administration
completely restored the alveolar architecture, such that there was no observable difference
in alveolar airspace and septa thickness between control and BPA-exposed fetal lungs.
Moreover, dexamethasone treatment also normalized the expression of the type I cell
marker in BPA-exposed fetal lungs, indicative of normal type I cell differentiation.
Given that the BPA-induced lung immaturity phenotype closely resembles that of
glucocorticoid deficient mice and dexamethasone was able to rescue this lung immaturity
phenotype, these findings suggest that prenatal exposure to BPA disrupts fetal lung
maturation likely through altering the glucocorticoid signaling pathway. Indeed, a recent study
using in vitro yeast bioassays shows that BPA acts as a potent glucocorticoid receptor
antagonist31. Thus, we further hypothesized that BPA may disrupt fetal lung maturation
by suppressing the glucocorticoid signaling pathway. To address this hypothesis, we
determined if prenatal exposure to BPA resulted in reduced expression of key
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glucocorticoid target genes in the fetal lung. We describe in Chapter 3 that the expression
of both epithelial sodium channel γ (ENaCγ) and glutathione peroxidase (GPX), two wellknown glucocorticoid target genes in the lung32, was dramatically decreased in BPAexposed fetal lungs. Collectively, these findings suggest that BPA likely functions as a
glucocorticoid receptor antagonist to disrupt fetal lung maturation.

2.4 Specific Aim 3
To determine the precise molecular mechanisms of the adverse effects of BPA on the
glucocorticoid signaling pathway.
In Chapter 3 we provide evidence that prenatal exposure to BPA disrupts fetal lung
maturation likely through altering the glucocorticoid signaling pathway, but the precise
molecular mechanisms remain obscure. Given that BPA diminished the expression of
ENaCγ, a well-known glucocorticoid receptor target gene, in fetal lungs, we used this target
gene to delineate the molecular pathway through which BPA exerts its effects on lung
epithelial cells.
Therefore, we hypothesized that BPA may repress ENaCγ expression through inhibition
of glucocorticoid receptor signaling in lung epithelial cells. To address this hypothesis,
the human A549 lung epithelial cell line was used as an in vitro model system. As a first
step, in Chapter 4 we validated our in vitro cell model by demonstrating a robust
concentration-dependent suppression of ENaCγ expression following BPA exposure. We
also showed that both dexamethasone and siRNA-mediated knockdown of GR expression
blocked/abrogated the inhibitory effects of BPA on ENaCγ expression, suggesting that
BPA repress ENaCγ expression via inhibition of GR activity. Given that BPA is known to
function as a pro-inflammatory factor via the estrogen receptor β (ERβ)33–35, and a mutual
antagonism exists between the pro-inflammatory transcriptional factor NF-κB and GR36–
39

, we then explored and provide evidence supporting the notion that BPA acts on ERβ to

activate the NF-κB signaling pathway, which in turn leads to diminished GR activity and
consequent repression of ENaCγ expression in lung cells. Thus, our present findings reveal
a novel BPA signaling pathway that involves ERβ, NF-κB and GR, and suggest a molecular
pathway through which BPA may disrupt fetal lung development.
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1

PRENATAL EXPOSURE TO BISPHENOL A DISRUPTS
MOUSE FETAL LUNG DEVELOPMENT1

Reproduced (adapted) with permission from: Hijazi A, Guan H, Cernea M, Yang K (2015) Prenatal exposure

to bisphenol A disrupts mouse fetal lung development. FASEB J 29(12): 4968-77.
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3.1 Introduction
Exposure to endocrine-disrupting chemicals (EDCs) has become a major public concern
as a result of its association with a wide range of disorders in humans, including
reproductive, neurologic, behavioral, respiratory, and metabolic disorders as well as
cancers1,2. In particular, bisphenol A (BPA), one of the most prevalent EDCs in the
environment, has attracted enormous worldwide attention because BPA exposure has been
shown to cause various adverse effects in both humans and experimental animals3,4.
Humans are routinely exposed to BPA through air and contact with numerous consumer
products, including plastic ware, the inner linings of canned food containers, and various
paper products, as well as contaminated water and food5. Importantly, BPA has been shown
to accumulate in human body tissues, resulting in much higher exposure levels than
previously thought6. Of particular concern is BPA exposure during pregnancy, a critical
period during which the developing fetus is especially vulnerable to this EDC7,8. Indeed,
appreciable amounts of bioactive BPA have been detected in amniotic fluid, umbilical cord
blood, and fetal and maternal blood of pregnant women9,10. Furthermore, prenatal exposure
to BPA is known to affect the development of various fetal organs, including brain11,12,
heart13, mammary gland14,15, ovary16,17, and uterus18.
Abnormal fetal organ development may account for the adverse health outcomes observed
in later life after prenatal BPA exposure3. In humans, exposure to BPA during various
periods of development is associated with impaired lung function19 and the development
of asthma20,21 and wheeze22 in children. Recently high serum levels of BPA have been
linked to chronic obstructive pulmonary disease23. In addition, perinatal BPA exposure
induces asthma in mice24–26. More importantly, recent studies suggest that exposure to BPA
exclusively during the prenatal period is sufficient to disrupt lung function during later life.
For example, prenatal, but not postnatal, BPA exposure has been linked to diminished lung
function and chronic wheeze in children27. This finding is supported by an animal study
that demonstrated that exposure to BPA during gestation, but not lactation, leads to asthma
in mice28. Collectively, these findings show that prenatal BPA exposure is detrimental to
lung function, suggesting that BPA may alter fetal lung development, thus leading to lung
dysfunction and diseases in later life. However, evidence in support of this hypothesis is
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lacking. Therefore, the goal of the present study was to address this important question
using the mouse as an experimental model.

3.2 Materials and Methods
3.2.1 Animal Experiments
The use of animals in this study was approved by the Council on Animal Care at the
University of Western Ontario, following the guidelines of the Canadian Council on
Animal Care. Breeding pairs of adult C57BL/6 mice were purchased from Charles River
Laboratories (Wilmington, MA, USA). Mice were housed under standard conditions and
provided with food and water ad libitum. To minimize background exposure to BPA
beyond treatment regimen, mice were housed in polystyrene cages and maintained at
humidity- and temperature-controlled rooms on a 12 h/12 h light–dark cycle. For
experiments, female mice 6 to 8 wk old were placed overnight with males, and pregnancy
was determined the next morning by the observation of a vaginal plug. Plugged females
were separated from the males and gestational days counted, with the day of the vaginal
plug being embryonic day (E) 0.5. Pregnant mice were randomly assigned to receive 1 of
the following 4 diets: control diet (phytoestrogen-free food pellets supplemented with 7%
corn oil; TD.120176; Harlan Teklad, Madison, WI, USA); control diet supplemented with
5 mg BPA/kg (TD.120465; Harlan Teklad); control diet supplemented with 25 mg BPA/kg
(TD.120466; Harlan Teklad); or control diet supplemented with 50 mg BPA/kg
(TD.120177, Harlan Teklad). Mice were fed the above diets from E7.5 to E18.5. The
gestational age of E7.5 was chosen as the start of the feeding regimen in order to avoid any
confounding effects of BPA on embryo implantation. For the rescue studies, saline or
dexamethasone (0.4 mg/kg; Omega, Montreal, QC, Canada) was injected subcutaneously
on E16.5 and E17.5 to the control and BPA-fed pregnant mice, respectively. At E18.5,
animals were euthanized with CO2, fetuses were recovered by caesarean section, and their
weights recorded. In addition, maternal weight, number of pups, and the number of
reabsorption sites per uterine horn were noted. Fetal lungs were either fixed in 4%
paraformaldehyde or frozen rapidly in liquid nitrogen and stored at −80°C.
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3.2.2 Histology
Fetal lungs were fixed in 4% paraformaldehyde in 0.1 M PBS buffer, dehydrated, and
embedded in paraffin. Using a rocking microtome, the lungs were carefully sectioned; 5
μm sections were transferred to Superfrost/Plus microscope slides (Fisher Scientific,
Whitby, ON, Canada). Sections were stained using a standard hematoxylin and eosin
protocol29. Selected lung sections were also stained with periodic acid–Schiff (PAS).
Stained lung sections were examined with a light microscope. Images were captured at ×20
and ×40 magnifications. For quantitative morphometry, a total of 16 pups from 4 different
litters (4 pups/litter) per treatment group (i.e., control and BPA) were analyzed. Alveolar
size, alveolar wall thickness, and PAS staining were measured with Image ProPlus 6.0
(Silver Springs, MD, USA) on 10 randomly selected micrographs from each individual
section, and a total of 16 sections (1 section was randomly selected per pup) per treatment
group were analyzed and counted. All analyses were performed by 2 investigators who
were masked to the animal number and experimental group.

3.2.3 Immunohistochemistry
Fetal lung tissue sections were prepared as described above. After deparaffinization and
rehydration, tissue sections were incubated sequentially in 3% hydrogen peroxide (Fisher
Scientific) for 10 min to reduce endogenous peroxidase activity and then in blocking
reagent solution (Background Sniper, catalog BS966; Biocare Medical, Concord, CA,
USA) for 10 min to prevent nonspecific background labeling. Tissue sections were
incubated in rabbit surfactant protein C (1:200, catalog WRAB-76694; Seven Hills
Bioreagents, Cincinnati, OH, USA) overnight at 4°C. Sections were then incubated with
biotinylated goat anti-rabbit IgG (1:500; catalog PK-6102; Vector Laboratories,
Burlingame, CA, USA) for 30 min, ABC (1:500, catalog PK-6102; Vector Laboratories)
for 30 min, and 0.02% 3,3-diaminobenzidene (DAB chromogen, catalog DBC859 H, L10;
Biocare Medical) for 2 min. Tissue sections were dehydrated with alcohol and coverslipped
with Permount.
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3.2.4 Real-time quantitative reverse transcriptase PCR
The relative abundance of various mRNAs was assessed by a 2-step real-time quantitative
reverse transcriptase PCR (qRT-PCR), as described previously29 with the following
specific modifications. Briefly, total RNA was extracted from fetal lung tissues using
RNeasy Mini Kit (Qiagen, Mississauga, ON, Canada) coupled with on-column DNase
digestion with the RNase-Free DNase Set (Qiagen) according to the manufacturer’s
instructions. One microgram of total RNA was reverse transcribed in a total volume of 20
µl using the High Capacity cDNA Archive Kit (Applied Biosystems, Forest City, CA,
USA) following the manufacturer’s instructions. For every RT reaction set, 1 RNA sample
was set up without reverse-transcriptase enzyme to provide a negative control. Gene
transcript levels of glyceraldehyde phosphate dehydrogenase (GAPDH, housekeeping
gene, the expression level of which was found to be stable across all treatment groups),
aquaporin 5 (AQP5), surfactant protein (SP)-A, SP-B, SP-C, SP-D, versican, midkine, and
Ki-67 were quantified separately by predesigned and validated TaqMan Gene Expression
Assays (Applied Biosystems; Table 3.1) following the manufacturer’s instructions. Briefly,
gene expression assays were performed with the TaqMan Gene Expression Master Mix
(P/N #4369016; Applied Biosystems) and the universal thermal cycling condition (2 min
at 50°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C) on
the ViiA 7 Real-Time PCR System (Applied Biosystems).
The relative amount of various gene-specific mRNAs in each RNA sample was quantified
by the comparative Ct method (also known as the ΔΔCt method) using the Applied
Biosystems relative quantitation and analysis software according to the manufacturer’s
instructions. For each RNA sample, the amount of gene-specific mRNAs in BPA-exposed
fetal lungs is expressed relative to the amount of transcript present in the control lungs.

3.2.5 Western Blot Analysis
Western blot analysis was used to determine various protein levels, as described
previously29. Briefly, lung tissues were homogenized in 10 volumes of ice-cold 10 mM
sodium phosphate buffer, pH 7.0, and containing 0.25 M sucrose. Equal volumes of the
homogenates were mixed with SDS gel loading buffer (50 mM Tris-HCl, pH 6.8, 2%
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wt/vol SDS, 10% vol/vol glycerol, 100 mM DTT, and 0.1% wt/vol bromophenol blue),
and equal concentrations of this mixture were subjected to a standard 10% SDS-PAGE.
After electrophoresis, proteins were transferred to PVDF transfer membrane (Amersham
Hybond-P, catalog RPN303F; GE Healthcare Lifesciences, Baie D’Urfe, QC, Canada)
using a Mini Transfer Apparatus (Bio-Rad, Hercules, CA, USA). Nonspecific antibody
binding was blocked with 5% wt/vol milk in TTBS (0.1% vol/vol Tween-20 in Trisbuffered saline) for 1 h at room temperature. Membranes were then hybridized with
primary antibody (Ki-67; catalog ab15580, 1:1000 dilution; Abcam, Toronto, ON, Canada;
proliferating cell nuclear antigen [PCNA]: catalog 2586, 1:1000 dilution; Cell Signaling
Technology, Beverly, MA, USA; caspase-3: catalog 9662, 1:1000 dilution; Cell Signaling
Technology; SP-A: catalog AB78173, 1:2000 dilution; Abcam; SP-B: the gift of F.
Possmayer, 1:1000 dilution; AQP5: catalog LS-C-172028, 1:1000 dilution; LifeSpan
BioSciences, Seattle, WA, USA; GAPDH, catalog IMG-3073, 1:5000; Imgenex, Port
Coquitlam, British Columbia, Canada) overnight at 4°C. After 3 × 10 min washes with
TTBS, the membrane was incubated with the appropriate horseradish peroxidase–labeled
secondary antibody, either anti-rabbit (catalog HAF008, 1:500; Fisher Scientific) or antimouse (catalog G-202-C, 1: 10,000; Fisher Scientific) for 1 h at room temperature. After
another 3 × 10 min washes in TTBS, proteins were detected by chemiluminescence
(catalog WBLUR0500, Luminata Crescendo, Western HRP Substrate; Millipore,
Etobicoke, ON, Canada) and captured on the VersaDoc Imaging System (Bio-Rad).
Densitometry was performed on the images, and the level of various proteins was
expressed as a percentage of controls.

3.2.6 Corticosterone Assays
Blood samples were collected from fetuses on E18.5 in heparinized capillary tubes (catalog
22-260-950; Fisher Scientific) between 9 and 11 am, then centrifuged at 2000g for 10 min.
Blood samples were also collected in the same fashion from another group of fetuses at
E15.5. Plasma was then collected and stored at −80°C until use. Levels of corticosterone
in plasma samples (fetal plasma from 1 litter were pooled and used as 1 sample) were
determined with an ELISA Kit (catalog ab108821; Abcam) following the manufacturer’s
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instructions. To eliminate interassay variations, all samples were analyzed in triplicate in
1 assay, and the intra-assay coefficient of variation was <5%.

3.2.7 BPA Assays
Blood samples were collected from pregnant mice (n = 12) at E18.5, and plasma was
collected and pooled (n = 2–3). Pooled plasma samples were sent to NMS Labs (Willow
Grove, PA, USA), where unconjugated (free) BPA was measured by GC-MS.

3.2.8 Statistical Analysis
Results are presented as means ± SEM of 4 to 6 different litters, as indicated. Data were
analyzed by 1-way ANOVA followed by Tukey’s post hoc test or Student’s t test, as
indicated. Significance was set at P < 0.05.
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Table 3.1. TaqMan® gene expression assays for the mouse genes analyzed.
Gene Name

Assay ID

AQP5

Mm00437579_m1

SP-A

Mm00499170_m1

SP-B

Mm00455681_m1

SP-C

Mm00488144_m1

SP-D

Mm00486060_m1

GAPDH

Mm99999915_g1
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3.3 Results
3.3.1 Effects of BPA on fetal body weight and litter size
As a first step in exploring the effects of BPA on fetal organ development, we assessed
changes in fetal body weight and litter size at E18.5. There was no difference in either body
weight (Fig. 3.1 A) or litter size (Fig. 3.1 B) between control and BPA-exposed fetuses,
irrespective of BPA dose.
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Figure 3.1: BPA does not affect fetal body weight or litter size. Pregnant mice were fed a
control diet (phytoestrogen free food pellets) or the control diet supplemented with 5, 25,
or 50 mg BPA/kg food pellets from embryonic day (E) 7.5 to E18.5. On E18.5, mice were
sacrificed, fetal body weight (A) and litter size (B) were recorded. Data are presented as
means ± SEM (n=6 litters).
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3.3.2 BPA severely impairs fetal lung maturation
To determine whether prenatal BPA exposure affects structural maturation of the fetal lung,
standard histologic analysis was performed on fetal lungs collected at E18.5 from control
and BPA (5, 25, and 50 mg BPA/kg diet)-fed pregnant mice. We found that the overall
organization of fetal lungs (i.e., 4 right lobes and 1 left lobe flanking the heart) was not
altered by BPA. At a microscopic level, both subjective observations (Fig. 3.2 A) and
quantitative morphometric measurements (Fig. 3.2 B, C) revealed diminished alveolar
airspace (15% of control) and increased alveolar septa thickness (172% of control) in fetal
lungs exposed to 25 and 50 mg BPA/kg diet compared to control and 5 mg/kg BPA diet
groups. These characteristics are hallmarks of severe lung immaturity, closely resembling
the lung immaturity phenotype of several knockout mouse models30–32. Given that fetal
lungs exposed to 25 and 50 mg BPA/kg diet displayed similar defects in lung maturation,
subsequent biochemical analysis was performed only on lungs from fetuses exposed to the
25 mg BPA/kg diet.
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Figure 3.2: BPA severely impairs fetal lung maturation. Pregnant mice were fed a control
diet (phytoestrogen free food pellets) or the control diet supplemented with 5, 25, or 50 mg
BPA/kg food pellets from embryonic day (E) 7.5 to E18.5. On E18.5, mice were sacrificed,
and fetal lungs were collected, fixed and subjected to standard histological analysis.
Representative fetal lung histology from mice fed the control diet, the control diet
supplemented with 5 mg BPA/kg, 25 mg BPA/kg, and 50 mg BPA/kg are shown in (A).
Morphometric data of alveolar size and alveolar wall thickness are shown in (B and C).
Data are presented as mean ± SEM (***P<0.001; n=6 litters). Scale bar, 100 µm.
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3.3.3 BPA exposure levels
To confirm that the dose of BPA (25 mg/kg diet) was relevant to humans, we measured
maternal plasma levels of unconjugated (free) BPA at E18.5 and found them to be in the
range of 1.2 to 2.6 ng/ml (mean 1.7 ng/ml).

3.3.4 BPA increases cytoplasmic glycogen content without affecting
proliferation or apoptosis of alveolar epithelial cells
To determine whether the thickened alveolar septa was a result of altered epithelial cell
maturation, we compared cytoplasmic glycogen content, a well-known marker of fetal lung
epithelial cell maturation32–35, between control and BPA-exposed fetuses. Intracellular
glycogen content was measured by staining fetal lung sections with PAS. We found that
fetal lungs from BPA-exposed mice displayed a significant increase (∼50%) in PAS
staining (Fig. 3.3 A, B). To further investigate whether changes in epithelial cell
proliferation or apoptosis also contributed to the thickened alveolar septa, we examined
expression levels of markers of proliferation and apoptosis. We showed that both mRNA
and protein levels of Ki-67 as well as protein levels of PCNA and caspase-3 were not
altered by BPA (Fig. 3.4).
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Figure 3.3: BPA increases cytoplasmic glycogen deposition. Pregnant mice were fed a
control diet (phytoestrogen free food pellets) or the control diet supplemented with 25 mg
BPA/kg food pellets from embryonic day (E) 7.5 to E18.5. On E18.5, mice were sacrificed,
and fetal lungs were collected, fixed and subjected to standard PAS staining.
Representative PAS staining of cytoplasmic glycogen deposition, as indicated by arrows,
in fetal lung sections from mice fed the control diet and the control diet supplemented with
25 mg BPA/kg are shown in (A). Morphometric data of cytoplasmic PAS staining is shown
in (B). Data are presented as mean ± SEM (**P<0.01; n=6 litters). Scale bar, 20 µm
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Figure 3.4: BPA does not alter the expression of proliferation and apoptosis marker
proteins. Pregnant mice were fed a control diet (phytoestrogen free food pellets) or the
control diet supplemented with 25 mg BPA/kg food pellets from embryonic day (E) 7.5 to
E18.5. On E18.5, mice were sacrificed, and fetal lungs were collected, flash frozen in liquid
nitrogen, and stored at -80°C. Levels of PCNA protein, Ki67 protein (A, B and D;
proliferation marker) and caspase-3 protein (A and C; apoptosis marker) were determined
by standard western blot analysis and immunohistochemistry. Data are presented as means
± SEM (n=6 litters). Scale bar, 20 µm.
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3.3.5 BPA disrupts alveolar epithelial type I cell differentiation
To define the precise cellular defects in the BPA-induced lung immaturity phenotype, we
measured alveolar epithelial types I and II cell-specific markers, and used them as
indicators of epithelial cell differentiation. We found that both mRNA and protein levels
of SP-A, -B, -C, and -D type II cell markers36,37, were similar between control BPAexposed fetal lungs (Fig. 3.5). In marked contrast, both mRNA and protein levels of AQP5,
a water channel protein whose expression is restricted to type I cells during lung
development38,39, were dramatically reduced in BPA-exposed fetal lungs (Fig. 3.6).
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Figure 3.5: BPA does not affect alveolar epithelial type II cell differentiation. Pregnant
mice were fed a control diet (phytoestrogen free food pellets) or the control diet
supplemented with 25 mg BPA/kg food pellets from embryonic day (E) 7.5 to E18.5. On
E18.5, mice were sacrificed, and fetal lungs were collected, flash frozen in liquid nitrogen,
and stored at -80°C. The mRNA (A) and protein (B-E) levels of surfactant proteins (SP-A,
SP-B, SP-C, and SP-D) were determined by qRT-PCR, western blotting and
immunohistochemistry (SP-C), respectively. Data are presented as means ± SEM (n=6
litters). Scale bar, 20 µm.
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Figure 3.6: BPA disrupts alveolar epithelial type I cell differentiation. Pregnant mice were
fed a control diet (phytoestrogen free food pellets) or the control diet supplemented with
25 mg BPA/kg food pellets from embryonic day (E) 7.5 to E18.5. On E18.5, mice were
sacrificed, and fetal lungs were collected, flash frozen in liquid nitrogen, and stored at 80°C. Levels of AQP5 protein (A and B) and mRNA (C) were determined by qRT-PCR
and western blotting, respectively. Data are presented as means ± SEM (***P˂0.001; n=6
litters).
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3.3.6 BPA deceases the expression of epithelial sodium channel γ
and glutathione peroxidase but not versican and midkine
To determine whether BPA interferes with glucocorticoid signaling, we first examined
changes in the expression of epithelial sodium channel γ (ENaCγ) and GPX, 2 well-known
glucocorticoid target genes in the lung40. We showed that levels of both ENaCγ and
glutathione peroxidase (GPX) proteins were significantly decreased in BPA-exposed fetal
lungs compared to controls (Fig. 3.7A–C). We also examined the expression of another 2
glucocorticoid target genes, but we found that mRNA levels of both versican and midkine
were not different between control and BPA-exposed fetal lungs (Fig. 3.7D).
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Figure 3.7: BPA decreases the expression of glucocorticoid target genes. Pregnant mice
were fed a control diet (phytoestrogen free food pellets) or the control diet supplemented
with 25 mg BPA/kg food pellets from embryonic day (E) 7.5 to E18.5. On E18.5, mice
were sacrificed, and fetal lungs were collected, flash frozen in liquid nitrogen, and stored
at -80°C. Levels of ENaCγ (A and B), GPX (A and C), Versican (D), and Midkine (D)
proteins were determined by western blotting. Data are presented as means ± SEM
(*P˂0.05; n=6 litters).
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3.3.7 BPA does not alter fetal plasma levels of corticosterone
We then examined changes in fetal plasma corticosterone levels. We found that plasma
levels of corticosterone were similar between control and BPA-exposed fetuses at E18.5
(Fig. 3.8A). To ascertain whether changes in corticosterone levels may precede the
gestational age at which the lung immaturity phenotype was observed, we also measured
fetal plasma corticosterone levels at E15.5. Our results showed that BPA did not alter
corticosterone levels at this gestational age (Fig. 3.8B).
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Figure 3.8: BPA does not alter fetal plasma levels of corticosterone. Pregnant mice were
fed a control diet (phytoestrogen free food pellets) or the control diet supplemented with
25 mg BPA/kg food pellets from embryonic day (E) 7.5 to E15.5 or E18.5. On E15.5 and
E18.5, mice were sacrificed, and blood samples collected from fetuses. Plasma was then
collected, and stored at -80°C until use. Levels of corticosterone at E18.5 (A) and E15.5
(B) were determined in fetal plasma samples using an ELISA Kit. Data are presented as
means ± SEM (n=6 litters).
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3.3.8 Maternal dexamethasone administration rescues the lung
immaturity phenotype
To provide further insight into the possibility that BPA interferes with glucocorticoid
signaling, we determined whether synthetic glucocorticoid administration would rescue the
BPA-induced lung immaturity phenotype. To do so, we treated BPA-exposed pregnant
mice with two courses of dexamethasone injections at E16.5 and E17.5, respectively. We
showed that maternal dexamethasone administration completely restored the alveolar
architecture such that there was no observable difference in alveolar airspace and septa
thickness between control and BPA-exposed fetal lungs (Fig. 3.9A). Moreover,
dexamethasone treatment also normalized AQP5 protein expression in BPA-exposed fetal
lungs (Fig. 3.9B, C).
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Figure 3.9: Maternal dexamethasone administration rescues the lung immaturity
phenotype. Pregnant mice were fed a control diet (phytoestrogen free food pellets) or the
control diet supplemented with 25 mg BPA/kg food pellets from embryonic day (E) 7.5 to
E18.5. On E16.5 and E17.5, control and BPA fed mice were injected subcutaneously with
saline and dexamethasone (0.4 mg/kg), respectively. On E18.5, mice were sacrificed, fetal
lungs were collected, fixed, and subjected to standard histological analysis, or flash frozen
in liquid nitrogen, and stored in -80°C. Representative fetal lung histology from mice fed
the control diet, the control diet supplemented with 25 mg BPA/kg, and the control diet
supplemented with 25 mg BPA/kg + dexamethasone are shown in (A). Protein levels of
AQP5 (B and C) were determined by standard western blot analysis. Data are presented as
mean ± SEM (***P<0.001; n=6 litters). Scale bar, 100 µm.
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3.4 Discussion
Numerous studies have shown that BPA permanently alters organ growth and
development, ultimately leading to tissue dysfunction and various diseases later in life3,4,41.
Although developmental exposure to BPA is linked to impaired lung function and the
development of asthma in both humans and experimental animals, to our knowledge, the
role of BPA in fetal lung development had never been explored in either human
clinical/epidemiologic studies or animal models. In the present study, we demonstrate that
prenatal exposure to environmentally relevant doses of BPA via maternal diet severely
impairs fetal lung maturation in the mouse. We also provide evidence suggesting that these
effects of BPA are mediated at least in part through the glucocorticoid-signaling pathway.
Thus, our present findings highlight the potential adverse effects of BPA on human fetal
lung maturation and suggest a fetal origin for BPA-induced lung dysfunction and diseases.
However, we recognize that prenatal exposure to BPA in humans likely contributes to a
small proportion of cases of abnormal fetal lung development in instances where fetuses
are exposed to high levels of BPA during critical periods of development.
The BPA dosages used in our study (5, 25, and 50 mg/kg diet; equivalent to 1, 5, and 10
mg BPA/kg body weight/d) were designed with the maximal dosage (i.e., 10 mg/kg/d) to
mimic that used in a previous study on Avy mice in which BPA shifted the coat color and
altered the methylation status of the Agouti gene without any adverse effects42.
Furthermore, these dosages were also several orders of magnitude below the lowest
observable adverse effect level (LOAEL) for rodents (50 mg/kg/d), as established by the
U.S. Environmental Protection Agency43. Importantly, the middle dose produced an
average maternal plasma BPA concentration of 1.7 ng/ml, which is at the lower end of the
range (0.5–22.3 ng/ml) reported in pregnant women in the United States44. This
concentration is 10 times lower than the estimated maximal concentration (20 ng/ml, which
is estimated to be maximal because pregnant mice were exposed for a total of 11 d in the
present study vs. 28 d in the previous study) based on one previous mouse study in which
the same BPA-containing food pellet (5 mg/kg; equivalent to 1 mg BPA/kg body weight/d)
was fed before and throughout pregnancy and lactation11. Although the precise reasons for
our apparent underestimation of plasma BPA concentrations are unclear, it is possible that
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BPA degradation may be a contributing factor, because maternal plasma samples were
stored at −80°C for over 1 year before being analyzed for BPA concentrations.
Nevertheless, even the estimated maximal maternal BPA concentration of 20 ng/ml falls
within the range of those reported previously in pregnant women, indicating that the dosage
used in the present study is relevant to humans.
Previous studies have shown that prenatal BPA exposure via various routes and at different
dosages can lead to fetal growth restriction in animal models, although not all studies
demonstrated such an effect4. In the present study, we found no effect of BPA on fetal body
weight or litter size, regardless of the dosage. This demonstrates that the BPA dosages used
in this study have no adverse effects on overall fetal growth morphometry. We then
examined the effects of BPA on the structural maturation of fetal lung at E18.5, a critical
organ essential for extrauterine survival and a time point at which all previous studies on
fetal lung maturation were carried out31–34. By standard histologic analysis, we showed that
BPA at both 25 and 50, but not 5, mg/kg diet severely impaired fetal lung maturation, as
evidenced by diminished alveolar airspace and thickened alveolar septa, reminiscent of the
impaired lung maturation phenotype of several knockout mouse models. These include
glucocorticoid receptor (GR)30–33; corticotrophin-releasing hormone (CRH)31; critical
signal transduction proteins, such as extracellular signal–regulated kinase 3 (Erk3)32;
differentiation genes of lung type I cells, such as T1α45, and several transcription factors
that play key roles in development such as hypoxia-inducible factor (HIF)-1α35, HIF-2α46,
and specificity protein 3 (Sp3)47; and c/ebpα34.
To ascertain whether the thickened alveolar septa were a result of altered epithelial cell
maturation, we examined cytoplasmic glycogen levels in fetal lung sections from both
control and BPA-exposed mice. BPA-exposed fetal lungs showed a ∼50% increase in
glycogen content, a well-known indicator of immature epithelial cells and the level of
which has also been shown to be elevated in GR33, Erk332, HIF-1α35, and c/ebpα34 knockout
mice. We then determined whether altered proliferation and/or apoptosis contributed to the
observed increase in alveolar septal wall thickness. Our results suggested that prenatal
exposure to BPA unlikely affected epithelial cell proliferation or apoptosis because both
mRNA and protein levels of Ki-67 as well as protein levels of PCNA and caspase-3
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(universal markers of cell proliferation and apoptosis, respectively) were similar between
control and BPA-exposed fetal lungs. Our present findings also corroborated studies that
reported similar findings using mice deficient in the cell cycle inhibitors p21/p5748.
However, our findings deviate from those reported in GR-null mice, which showed
hyperproliferation in the fetal lung mesenchyme component49.
The functional units of lungs are composed of alveolar epithelial type I and type II cells,
which are responsible for gas exchange and surfactant production, respectively50. Type II
cells, derived from immature pretype II cells, are considered the progenitors of both
epithelial cell types, capable of proliferation and differentiation into type I cells50. The type
II cells are marked by the expression of SP-A, SP-B, SP-C, and SP-D36,37. We showed that
prenatal BPA exposure did not alter the expression of any SPs, indicating that type II cell
differentiation was not affected. Similar findings were also reported in T1α45, Sp347, and
sorting nexin 5 (Snx5)-null mice51, which displayed the same lung immaturity phenotype
as observed in the present study. Having established the lack of an effect of BPA on type
II cell differentiation, we then examined the status of type I cell differentiation. We did so
by measuring the expression level of AQP5, a type I cell-specific marker and a key water
channel protein involved in the transcellular movement of water across the type I cells38,39.
We showed that levels of AQP5 protein were dramatically decreased in BPA exposed fetal
lungs, indicative of impaired differentiation of type I cells. This contention is supported by
a previous study showing a similar lung immaturity with disrupted type I cell
differentiation in mice deficient in the type I cell differentiation gene T1α45. Decreased
AQP5 expression, and by inference impaired type I cell differentiation, was also observed
in fetal lungs of several mutant mouse models, including a locked-in mutant mouse model
with a disrupted thyroid hormone receptor corepressor function52, GR33 and Snx551deficient mice, and mice harboring a silencing mutation in the GATA-6 transcription
factor53. Taken together, these findings demonstrate that prenatal exposure to BPA impairs
type I, but not type II, epithelial cell differentiation.
Given that glucocorticoids play a key role in fetal lung maturation40 and that our BPAinduced lung immaturity phenotype closely resembles that of glucocorticoid deficient (i.e.,
CRH−/− and GR−/−) mouse models31,33, we hypothesized that BPA disrupts fetal lung
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maturation by suppressing glucocorticoid signaling. As a first step in testing this
hypothesis, we determined whether prenatal exposure to BPA resulted in reduced
expression of key glucocorticoid target genes in the lung. We showed that the expression
of both ENaCγ and GPX was significantly decreased in BPA-exposed fetal lungs. This
repression can be achieved by either decreasing circulating levels of corticosterone or
antagonizing glucocorticoid actions. Our examination found no evidence to support the
first possibility because fetal plasma levels of corticosterone were not altered at either
E18.5, when the lung immaturity phenotype was observed, or E15.5, a critical time point
just before terminal lung differentiation. More importantly, maternal dexamethasone
administration, a common intervention in managing high-risk pregnancies with threatened
preterm delivery to promote fetal lung maturation54, rescued the lung immaturity
phenotype and normalized AQP5 protein expression. Thus, our data support the possibility
that BPA functions as a glucocorticoid antagonist to disrupt fetal lung maturation. Indeed,
one recent study using in vitro yeast bioassays found that BPA acts as a GR antagonist,
with a drug concentration causing 50% inhibition of 67 μM55. However, the lack of a
change in expression of cell proliferation markers as well as some of the glucocorticoid
target genes (i.e., versican and midkine) in the present study is not entirely compatible with
a glucocorticoid-mediated signaling pathway because fetal lungs from GR-null mice
exhibit hyperproliferation in the mesenchyme component49. This suggests that the BPAinduced lung immaturity phenotype is partially mediated through glucocorticoid signaling.
Furthermore, given that circulating levels of corticosterone in fetal mice increase
dramatically at E16.5 to drive the final stages of fetal lung maturation56, we anticipate that
the BPA-induced lung immaturity phenotype would be evident before E18.5 (e.g., E16.5),
similar to that reported in GR-null mice30. Obviously, future studies will be required to
confirm this as well as to provide definitive evidence in support of BPA acting as a
glucocorticoid antagonist in fetal lung cells.
In conclusion, the present study demonstrated that BPA disrupts fetal lung maturation
partially via the glucocorticoid signaling pathway. Although the long-term consequences
of our present findings remain to be determined, they suggest that BPA-induced lung
dysfunction and diseases in later life, as reported previously in mice and humans, may have
a fetal origin. Furthermore, because BPA pharmacokinetics (metabolism and clearance) is
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similar between humans and mice57, our present findings also underscore the potential
impact of BPA exposure during pregnancy on fetal lung development in humans.
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4

2

BISPHENOL A SUPRESSES GLUCOCORTICOID
TARGET GENE EXPRESSION VIA A NOVEL ERβ-NFkB-GR SIGNALING PATHWAY IN LUNG EPITHELIAL
CELLS2

The material in this chapter is based on a manuscript accepted (with minor revisions) to

Archives of Toxicology: Hijazi A, Guan H, and Yang K. Bisphenol A suppresses
glucocorticoid target gene expression via a novel ER-NF-B-GR signaling pathway in
lung epithelial cells. (2016)
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4.1 Introduction
Exposure to endocrine disrupting chemicals (EDCs) has been associated with a range of
human diseases including cancer, diabetes, obesity, and decreased fertility1,2. Bisphenol A
(BPA), one of the most prevalent EDCs in the environment, has gained world-wide
attention due to growing evidence of its association with adverse health effects in humans
and experimental animal models3,4. BPA is an industrial chemical used to manufacture
polycarbonate plastics, epoxy resins lining the inside of food and beverage containers,
thermal print papers and composites used in dental sealants5. The pervasiveness of BPA is
such that it is detected in the air, water and soil; making human exposure to BPA
unavoidable5. Biomonitoring studies have detected BPA at nanomolar concentrations in
human body fluids such as serum, milk, saliva, and urine collected from all over the
world5,6. Importantly, BPA has been shown to accumulate in human body tissues, thus
exposure levels are much higher than previously thought7. Emerging evidence suggests
that BPA may influence multiple endocrine-related signaling pathways during
development, resulting in adverse effects on various organs including the brain8,9, heart10,
mammary gland11,12, lungs13, liver14, ovary15,16, and uterus17.
We recently showed that prenatal exposure to BPA severely impaired fetal lung maturation
in the mouse, likely via the glucocorticoid (GC) signaling pathway13. Other studies have
shown that early life exposure to BPA interferes with lung developmental processes in
humans and animal models, resulting in abnormal lung structure and function later in life.
In children, exposure to BPA during various periods of development is associated with
impaired lung function18 and the development of asthma19,20 and wheeze21. In addition,
high serum levels of BPA have been linked to chronic obstructive pulmonary disease
(COPD)22. More importantly, recent studies suggest that exposure to BPA exclusively
during the prenatal period is sufficient to disrupt lung function later in life. For example,
prenatal, but not postnatal, BPA exposure has been linked to diminished lung function and
chronic wheeze in children23. This finding is supported by an animal study demonstrating
that exposure to BPA during gestation, but not lactation, leads to asthma in mice24.
Collectively, these findings show that prenatal exposure to BPA is detrimental to lung
development and function, however, the underlying mechanism remains elusive.
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Considering the critical role of the glucocorticoid receptor (GR) during fetal lung
development and the evidence that BPA can act as a GR antagonist, the present study was
undertaken to examine how BPA alters the GC signaling pathway using a human epithelial
cell line as a model system.

4.2 Materials and Methods
4.2.1 Reagents
Bisphenol A was purchased from Sigma-Aldrich Canada Ltd. (>99% purity; CAS 80-057; Oakville, ON) and dissolved in ethanol to prepare a 10 mM stock solution, and stored at
-20°C. BAY 11-7082 was purchased from Millipore (cat. no. 196871) and dissolved in
DMSO to prepare a 100 mM stock, and stored at -20°C. Dexamethasone was purchased
from Stemcell Technologies (cat. no. 05407) and dissolved in ethanol to a concentration of
4 mg/mL, and stored at -20°C.

4.2.2 Cell culture
A549 cells, an alveolar cell carcinoma-derived cell line, were obtained from the American
Type Culture Collection (Manassas, VA, USA). A549 lung cells were cultured in standard
growth medium consisting of RPMI 1640 media (Invitrogen), 10% fetal bovine serum
(FBS; Sigma), and 100 IU penicillin and 100 µg/mL streptomycin (Invitrogen). All cultures
were maintained in a humidified incubator at 37°C and 5% CO2. Growth medium was
replaced every other day.

4.2.3 Real time quantitative RT-PCR
The relative abundance of various mRNAs was assessed by a two-step real-time
quantitative RT-PCR (qRT-PCR), as described previously25 with the following specific
modifications. Briefly, total RNA was extracted from cells using RNeasy Mini Kit
(QIAGEN Inc., Mississauga, ON) coupled with on-column DNase digestion with the
RNase-Free DNase Set (QIAGEN) according to the manufacturer’s instructions. 1 µg of
total RNA was reverse-transcribed in a total volume of 20 µL using the High Capacity
cDNA Archive Kit (Applied Biosystems, Forest City, CA) following the manufacturer’s
instructions. For every RT reaction set, one RNA sample was set up without reverse-
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transcriptase enzyme to provide a negative control. Gene transcript levels of GAPDH
(housekeeping gene whose expression level was found to be stable across all treatment
groups), IκB-α, p65, and ENaCγ were quantified separately by pre-designed and validated
TaqMan® Gene Expression Assays (Applied Biosystems; Table 4.1) following the
manufacturer’s instructions. Briefly, gene expression assays were performed with the
TaqMan® Gene Expression Master Mix (Applied Biosystems; P/N #4369016) and the
universal thermal cycling condition (2 minutes at 50°C and 10 minutes at 95°C, followed
by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C) on the ViiATM 7 Real-Time PCR
System (Applied Biosystems).
The relative amounts of various gene specific mRNAs in each RNA sample was quantified
by the comparative CT method (also known as  CT method) using the Applied
Biosystems relative quantitation and analysis software according to the manufacturer’s
instructions. For each experiment, the amount of various gene specific mRNAs under
different treatment conditions is expressed relative to the amount of transcript present in
the untreated control.

4.2.4 Western blot analysis
Western blot analysis was used to determine various protein levels, as described
previously26. Briefly, A549 cells were lysed in SDS Sample Buffer (62.5 mM Tris–HCl,
pH 6.8, 2% w/v SDS, 10% v/v glycerol, 50 mM DTT and 0.01% w/v bromophenol blue).
Equal concentrations of the whole cell lysates, or cytosolic and nuclear extracts, were
subjected to a standard 10% SDS-PAGE. After electrophoresis, proteins were transferred
to PVDF transfer membrane (Amersham Hybond-P, cat. no. RPN303F, GE Healthcare
Lifesciences, Baie D'Urfe, QC) using a Bio-Rad Mini Transfer Apparatus. Nonspecific
antibody binding was blocked with 5% wt/vol milk in TTBS (0.1% vol/vol Tween-20 in
TBS) for 1 h at room temperature. Membranes were then hybridized with the appropriate
primary antibody (Table 4.2) overnight at 4°C. The membranes were probed with the
horseradish peroxidase-labeled secondary anti-rabbit antibody for 1 h at room temperature
the following day. Proteins were detected by chemiluminescence (cat. no. WBLUR0500,
Luminata Crescendo, Western HRP Substrate; Millipore, Etobicoke, ON) and visualized
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using the VersaDoc Imaging System (BioRad, UK). Densitometry was performed on the
images, and the level of various proteins was expressed as a percentage of controls.

4.2.5 siRNA-mediated knockdown of GR expression
To provide direct evidence for the involvement of the GR in mediating the effects of BPA
on ENaCγ expression, a siRNA-mediated knockdown approach was utilized27. Briefly,
A549 cells were plated on 6-well plates and cultured under standard conditions for 48 h.
Cells were then transfected with 20 nM of siRNA targeting human GR (siGENOME
SMARTpool- Human) in Opti-MEM I medium (Invitrogen) containing Lipofectamine™
3000 (Invitrogen), following the manufacturer’s instructions. Cells were also transfected
in an identical manner with 20 nM of the negative control #1 siRNA (cat. no. 4624,
Ambion) or with the transfection agent alone to serve as controls. At 48 h post-transfection,
cells were collected for western blot analysis. Alternatively, 36 h or 30 h after transfection,
cells were treated for 12 h or 24 h with 10 nM of BPA, respectively.

4.2.6 Statistical Analysis
Results are presented as mean ± SEM of four independent experiments, as indicated. Data
were analyzed using one-way ANOVA followed by Tukey’s post-hoc test, or Student’s t
test as indicated. Significance was set at p<0.05.

102

Table 4.1. TaqMan® gene expression assays for the human genes analyzed.
Gene Name

Assay ID

I-κBα

Hs00153283_m1

p65

Hs00153294_m1

ENaCγ

Hs00168918_m1

GAPDH

Hs02758991_g1
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Table 4.2. Antibodies for the proteins analyzed.
Antibody

Catalogue No.

Dilution

Company

GR

sc-8992

1:1,000

Santa Cruz
Biotechnology, Inc.,
Santa Cruz. CA

Epithelial sodium
channel-gamma

ab3468

1:1,000

Abcam, Toronto, ON

NF-kB p65

sc-372

1:1,000

Santa Cruz
Biotechnology, Inc.,
Santa Cruz. CA

IκB-α

sc-371

1:1,000

Santa Cruz
Biotechnology, Inc.,
Santa Cruz. CA

Hsp90

ab178854

1:5,000

Abcam, Toronto, ON

ERβ

sc-8974

1:1,000

Santa Cruz
Biotechnology, Inc.,
Santa Cruz. CA

ERα

sc-543

1:500

Santa Cruz
Biotechnology, Inc.,
Santa Cruz. CA

GAPDH

IMG-3073

1:5,000

IMGENEX, Port
Coquitlam, BC

Histone H3

06-755

1:5,000

Millipore, Temecula,
CA

β-Tubulin

IMG-5810

1:1,000

IMGENEX, Port
Coquitlam, BC

1:1,000

R&D Systems,
Minneapolis, MN,
USA

HRP-labeled antirabbit Antibody

HAF008
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4.3 Results
4.3.1 Concentration-dependent effects of BPA on ENaCγ expression
Given that BPA diminished the expression of ENaCγ, a well-known GR target gene28, in
fetal lungs, we used this GR target gene to delineate the molecular pathway through which
BPA exerts its effects on lung cells. As shown in Fig. 4.1, treatment with increasing
concentrations of BPA (1–1000 nM) for 24 h resulted in a concentration-dependent
decrease in levels of ENaCγ protein.
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Figure 4.1: Concentration-dependent effects of BPA on ENaCγ expression. A549 cells
were maintained for 4 h in serum-free medium and then treated with increasing
concentrations of BPA (1–1000 nM) for 24 h. At the end of treatment, levels of ENaCγ
protein were determined by western blotting. Data are presented as mean ± SEM of four
independent experiments (**P<0.01, ***P<0.001 vs. control).
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4.3.2 Effects of dexamethasone and siRNA-mediated knockdown of
GR on BPA inhibition of ENaCγ expression
As a first step in determining if BPA repression of ENaCγ expression occurs via inhibition
of GR activity, we treated cells with BPA in the presence and absence of dexamethasone,
a potent GR agonist. We first confirmed dexamethasone significantly increased both
ENaCγ mRNA and protein in A549 cells (Fig. 4.2A and 2B). We then showed that
treatment with dexamethasone counteracts the effects of BPA on both ENaCγ mRNA and
protein (Fig. 4.2A and 2B). However, since the expression level ENaCγ is much lower than
with dexamethasone alone, this suggests BPA may be a non-competitive inhibitor of the
GR. To provide definitive evidence for the involvement of GR in mediating the inhibitory
effects of BPA on ENaCγ, we conducted siRNA-mediated knockdown of GR expression.
We found that transient transfection of A549 cells with siRNA targeting GR resulted in
86% reduction in the levels of GR protein without altering levels of GAPDH protein (Fig.
4.2C). Furthermore, transfection with a negative control siRNA (i.e., scrambled siRNA)
did not affect levels of GR protein or GAPDH protein, demonstrating the specificity of the
siRNA-mediated knockdown of GR in A549 cells. Having established the efficacy of
siRNA-mediated knockdown of GR expression, we then determined the effects of BPA on
ENaCγ expression in these cells. We showed that GR knockdown resulted in the complete
loss of the ability of BPA to inhibit ENaCγ expression (Fig. 4.2D).
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Figure 4.2: Dexamethasone and siRNA knockdown of GR reverse the inhibitory effects
of BPA on ENaCγ expression. A549 cells were maintained for 4 h in serum-free medium
and then treated with either 10 nM BPA, 100 nM Dex or co-treated with 10 nM BPA and
100 nM Dex for 24 h. At the end of treatment, levels of ENaCγ mRNA (A) and ENaCγ
protein (B) were determined by qRT-PCR and western blotting, respectively. A549 cells
were transfected with 20 nM of GR siRNA, 20 nM negative control (i.e., scrambled)
siRNA or the transfection agent alone to serve as control. Forty-eight hours after
transfection, cells were lysed, and levels of GR protein were determined by western
blotting (C). GAPDH was used as a control to show the specificity of siRNA mediated
knockdown of GR. Alternatively, 24 h after transfection, cells were treated for 24 h with
or without 10 nM of BPA (D). At the end of treatment, levels of ENaCγ protein were
determined by western blot analysis. Data are presented as mean ± SEM of four
independent experiments (**P<0.01, ***P<0.001 vs. control).
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4.3.3 Effects of BPA on the selected key components of GR signaling
pathway
To determine the precise mechanism by which BPA represses GR activity, we analyzed
several key components of the GR signaling pathway. Given that HSP90 is associated with
unbound GR in the cytoplasm29, we reasoned that altered expression of HSP90 might be
one of the mechanisms by which BPA influences GR activity. As shown in Fig. 4.3A and
4.3B, levels of HSP90 protein were not altered by BPA treatment for either 12 h or 24 h.
We also measured and found no changes in the level of GR protein following BPA
treatment (Fig. 4.3C and 4.3D). We then determined GR nuclear translocation by
measuring GR protein levels in cytosolic and nuclear fractions following treatment with
BPA. As shown in Fig. 4.3E and 4.3F, levels of GR protein in cytosolic fraction were
significantly increased while those in nuclear fraction were significantly decreased
following BPA treatment.
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Figure 4.3: Effects of BPA on the GR signaling pathway. A549 cells were maintained for
4 h in serum-free medium and then treated with 10 nM BPA for either 12 h (A) or 24 h (B),
after which levels of HSP90 protein were determined by western blot analysis. A549 cells
were maintained for 4 h in a serum-free medium and then treated with 10 nM BPA for
either 12 h (C) or 24 h (D), after which levels of GR protein were determined by western
blot analysis. A549 cells were maintained for 4 h in a serum-free medium and then treated
with 10 nM BPA for 12 h, at the end of the treatment cytosolic (E) and nuclear extracts (F)
were subjected to western blotting for GR protein. Data are presented as mean ± SEM of
four independent experiments (*P<0.05, **P<0.01 vs. control).
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4.3.4 Effects of BPA on NF-κB expression and activity
Since a mutual antagonism exists between GR and NF-κB, and BPA is known to activate
NF-κB30–37, we hypothesized that BPA inhibits GR activity via induction of NF-κB. As a
first step in testing this hypothesis, we measured NF-κB expression and activation
following treatment with BPA for 12 and 24 h. We found that treatment with BPA for 12 h
(Fig. 4.4A and 4.4C) but not 24 h (Fig. 4.4B and 4.4D) resulted in an increase in levels of
both NF-κB (p65) mRNA and protein. Since NF-κB activation requires translocation of
the p65 subunit to the nucleus, we measured p65 protein level in cytosolic and nuclear
fractions following treatment with BPA for 12 h. We observed that BPA treatment
significantly increased levels of p65 protein in both cytosolic and nuclear fractions (Fig.
4.4E and 4.4F). To provide functional evidence for the involvement of NF-κB activation
in mediating BPA-induced inhibition of GR activity, we treated cells with BPA in the
presence and absence of BAY 11-7082, an irreversible inhibitor of NF-κB activation. We
showed that BAY 11-7082 abrogated the inhibitory effects of BPA on ENaCγ expression
(Fig. 4.4G).
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Figure 4.4: Involvement of NF-κB (p65) in BPA repression of ENaCγ expression. A549
cells were maintained for 4 h in serum-free medium and then treated with 10 nM BPA for
either 12 h or 24 h. At the end of treatment, levels of p65 mRNA (A and B) and p65 protein
(C and D) were determined by qRT-PCR and western blotting, respectively. A549 cells
were maintained for 4 h in serum-free medium and then treated with 10 nM BPA for 12 h,
at the end of the treatment cytosolic and nuclear extracts were subjected to western blotting
for p65 protein (E and F). A549 cells were maintained for 4 h in serum-free medium and
then treated with either 10 nM BPA, 10 µM BAY 11-7082 or pretreated for 1 h with 10
µM BAY 11-7082 and were then treated with 10 nM BPA for 24 h. At the end of treatment,
levels of ENaCγ protein were determined by western blot analysis. Data are presented as
mean ± SEM of four independent experiments (*P<0.05, **P<0.01, ***P<0.001 vs.
control).

112

4.3.5 Effects of BPA on IκB-α expression
The translocation of NF-κB to the nucleus is critically controlled through binding with its
inhibitory protein (IκB-α), and IκB-α expression is in turn induced by NF-κB activation in
a classic negative feedback fashion38–40. We found that levels of IκB-α mRNA and protein
were significantly decreased and increased following BPA treatment for 12 h (Fig. 4.5A
and 4.5C) and 24 h (Fig. 4.5B and 4.5D), respectively.
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Figure 4.5: Effects of BPA on IκB-α expression. A549 cells were maintained for 4 h in
serum-free medium and then treated with 10 nM BPA for either 12 h or 24 h. At the end
of treatment, levels of IκB-α mRNA (A and B) and IκB-α protein (C and D) were
determined by qRT-PCR and western blotting, respectively. For measuring IκB-α protein
expression, β-Tubulin was used as a loading control since IκB-α (molecular weight of 3541 kDa) and GAPDH (molecular weight of 37 kDa) have similar molecular weights. Data
are presented as mean ± SEM of four independent experiments (*P<0.05, **P<0.01 vs.
control).
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4.3.6 Effects of ICI 182780 on BPA-mediated NF-κB expression and
activation – involvement of ERβ
Since BPA can act as an inflammatory inducer via the estrogen receptor (ER)34,35, we
investigated the involvement of ER in mediating the effects of BPA on the NF-κB signaling
pathway. As shown in Fig. 6, treatment with the ER-specific antagonist ICI 182780 (10
μM) completely blocked BPA-induced changes in levels of both p65 protein (Fig. 4.6A)
and IκB-α protein (Fig. 4.6B). To link BPA activation of ER to BPA-induced repression
of ENaCγ expression, we determined the effects of ICI 182780 and found that treatment
with this ER antagonist abrogated the inhibitory effects of BPA on ENaCγ expression (Fig.
4.6C). Given that ICI 182780 does not discriminate ER and ER, we examined and found
that only ER protein is detected under basal conditions in A549 cells (Fig. 4.6D). To
provide evidence for the hierarchy of BPA signaling (i.e., ER-mediated NF-κB is upstream
of GR), we determined the effects of siRNA mediated knockdown of GR expression on
BPA-induced p65 expression (Fig. 4.7). As shown in Fig. 4.7, BPA was equally effective
in increasing levels of p65 protein in cells transfected with and without GR siRNA.
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Figure 4.6: Effects of the Estrogen Receptor-β pathway on BPA mediated NF-κB (p65)
expression and activation. A549 cells were maintained for 4 h in serum-free medium and
then treated with either 10 nM BPA, 100 nM ICI 182780 or pretreated for 1 h with 100 nM
ICI 182780 and were then treated with 10 nM BPA for 12 h or 24 h. At the end of treatment,
levels of p65 (A), IκB-α (B) and ENaCγ (C) protein were determined by western blot
analysis. Western blot analysis performed to examine the expression of estrogen receptor
subunits (ERα and ERβ) in A549 cells (D). Data are presented as mean ± SEM of four
independent experiments (*P<0.05, **P<0.01 vs. control).
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Figure 4.7: GR siRNA does not reverse the effects of BPA on p65 expression. A549 cells
were transfected with 20 nM of GR siRNA, 20 nM negative control (i.e., scrambled)
siRNA or the transfection agent alone to serve as control. Forty-eight hours after
transfection, cells were lysed, and levels of GR protein were determined by western
blotting (A). GAPDH was used as a control to show the specificity of siRNA mediated
knockdown of GR. Alternatively, 36 h after transfection, cells were maintained for 4 h in
serum-free medium and then treated for 12 h with or without 10 nM of BPA (B). At the
end of treatment, levels of p65 protein were determined by western blot analysis. Data are
presented as mean ± SEM of four independent experiments (*P<0.05, **P<0.01,
***P<0.001 vs. control).
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4.4 Discussion
During fetal life, the GC-signaling pathway is essential in the development of major organs
such as the brain, lung, liver and kidneys41. We recently demonstrated that prenatal
exposure to environmentally relevant doses of BPA severely impairs fetal lung maturation
in the mouse13. We also provided evidence that these effects are likely mediated through
the GC signaling pathway, however, the precise molecular mechanisms remained
obscure13. The present study demonstrates that BPA acts on ERβ to activate the NF-κB
signaling pathway, which in turn leads to diminished GR activity and consequent
repression of ENaCγ expression in lung epithelial cells. Thus, our present findings reveal
a novel BPA signaling pathway that involves ERβ, NF-κB and GR.
The epithelial sodium channel (ENaC) is a universally recognized GC-target gene, as there
is extensive evidence that ENaC expression can be regulated by glucocorticoids,
particularly in the lungs28. Several studies demonstrate that dexamethasone increases the
expression of all three ENaC subunits in a time-dependent manner in A549 cells42,43. In
addition, GR knockout mouse studies measured the expression of the three ENaC subunits
as an indication of ablated GR response in the lungs44,45. Interestingly, although ENaCγ
expression is significantly reduced in the lung of GR-null mice, expression of the ENaC α
and β subunits is relatively unaltered compared with the lungs of WT mice44,45. Considering
that our previous study in mice showed that the expression of ENaCγ was significantly
decreased in BPA-exposed fetal lungs, we investigated the effects of nanomolar
concentrations of BPA on the expression of ENaCγ in lung epithelial cells. We show a
robust concentration-dependent suppression of ENaCγ expression following BPA
exposure. Further, we showed that dexamethasone blocked the inhibitory effects of BPA
on ENaCγ mRNA and protein expression, suggesting that BPA may function to suppress
GR signaling. Importantly, siRNA-mediated knockdown of GR expression completely
abrogated the inhibitory effects of BPA on ENACγ expression. Taken together, these
findings demonstrate that BPA suppresses ENaCγ expression via inhibition of GR activity.
In the absence of GC stimulation, GR resides in the cytosol complexed with a variety of
proteins, particularly HSP9046,47. The binding of GC to the cytoplasmic GR results in its
release from its chaperone proteins and rapid nuclear translocation47. Within the nucleus,
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GR induces transcription of genes by binding to specific DNA elements (GREs) at the
regulatory sequences of GR-target genes47. To determine the mechanism by which BPA
represses GR function, we analyzed several key components of the GR signaling pathway.
HSP90 association with GR is essential for maintaining the receptor in a high affinity
binding state. Studies in vitro show that GR immediately loses its ability to bind to GCs
when stripped of HSP9048,49. Considering the important role of HSP90 in retaining GR
activity, we postulated that changes in HSP90 protein expression would lead to a decrease
in GR affinity and GC resistance. Our results suggested that this was unlikely as protein
levels of HSP90 were similar between control and BPA treated cells. Next, we measured
the levels of GR protein in lung cells following BPA treatment, and found that BPA
treatment did not alter the level of GR protein. We then investigated whether BPA inhibited
GR activity through inhibition of GR nuclear translocation, and found a significant
decrease in GR protein in the nuclear fraction of cells treated with BPA. Taken together,
these results suggest that BPA likely inhibits GR activity through decreasing GR nuclear
translocation.
The nuclear factor-κB (NF-κB) transcription factor is a heterodimeric protein that
comprises a p50 and a transcriptionally active p65 subunit50. NF-κB is a central mediator
of the inflammatory process and a key participant in innate and adaptive immune
responses. Recently, BPA has been shown to function as an inflammatory inducer, since
BPA activates the NF-κB pro-inflammatory pathway in various cell types30–37. A mutual
antagonism exists between GR and NF-κB, whereby NF-κB represses GR and vice
versa50,51. This mutual antagonism is mediated solely through the p65 subunit of NFκB50,51. Studies have indicated several mechanisms by which the physical interaction of
NF-κB and GR can lead to mutual antagonism. First, in the cytoplasm, the direct interaction
between activated NF-κB and GR has been reported as one of the mechanisms impairing
GR nuclear translocation52. Second, in the nucleus53,54, NF-κB and GR may compete for
co-activators and/or by disturb their interaction with the basal transcription machinery and
thus inhibit transcription of target genes50,53,54. We therefore postulated that the inhibitory
effects of BPA on GR activity may be a result of NF-κB activation (p65) by BPA. As a
first step in testing this hypothesis, we examined both the expression and activation of NFκB (p65) in A549 cells following BPA treatment. We found that BPA significantly
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increased NF-κB expression and activity, suggesting that BPA induced NF-κB activation
in this cell line. In order to examine the role of NF-κB in the repression of GR-mediated
gene activation following BPA treatment, we used BAY 11-7082, a selective and
irreversible inhibitor of NF-κB activation. We showed that BAY 11-7082 abrogated the
inhibitory effects of BPA on ENaCγ expression, indicating the involvement of NF-κB in
BPA-mediated repression of GR activity.
It is well established that the activation of NF-κB is controlled by proteosomal degradation
of its inhibitory subunit, IκB-α, which binds to and sequesters it in the cytosol, preventing
the interaction of NF-κB with DNA to induce gene expression38,39. The IκB family of
proteins each have slightly different functions, but most are directly upregulated by NF-κB
activation38,39. IκB-α’s unique role in NF-κB regulation is indicated by the constitutive
nuclear activation of NF-κB in hematopoietic tissues from IκB-α knockout mice55.
Moreover, constitutive NF-κB activation in Hodgkin's disease-derived cell lines is a
consequence of defective IκB-α56. To ascertain whether increased NF-κB activity were a
result of altered IκB-α expression, we examined IκB-α mRNA and protein expression in
BPA-treated cells. BPA treatment for 12 h resulted in a significant decrease in both IκB-α
mRNA and protein expression. Furthermore, since IκB-α expression is expected to increase
with prolonged NF-κB activation, we next examined mRNA and protein expression
following BPA exposure for 24 h. We showed that levels of IκB-α mRNA and protein were
significantly increased following BPA exposure for 24 h, indicative of prolonged NF-κB
activation in A549 cells.
The ability of estrogen to modulate inflammatory response via interaction with ERs (ERα
and ERβ) has been extensively established57. BPA is known to mimic estrogen properties
in cells through binding to both ERα and ERβ, with a 10-fold higher affinity for ERβ58. To
examine the involvement of ER in BPA-induced NF-κB activation, we treated cells with
BPA in the presence and absence of the ER-specific antagonist ICI 182780. We showed
that ICI 182780 abrogated the effects of BPA on NF-κB (p65) and IκB-α, suggesting that
ER is involved in mediating BPA-induced activation of the NF-κB signaling pathway. To
link ER to BPA inhibition of ENaCγ expression, we examined and found that treatment of
A549 cells with ICI 182780 completely abrogated the inhibitory effects of BPA on ENaCγ
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expression. Given that ERα is not expressed in the A549 cell line, our data suggest that
ERβ is involved in mediating BPA-induced activation of the NF-κB signaling pathway.
In conclusion, the present study demonstrates for the first time that BPA acts on ERβ to
activate the NF-κB signaling pathway, which in turn leads to diminished GR activity and
consequent repression of ENaCγ expression in lung epithelial cells. Thus, the present study
reveals a novel BPA signaling pathway that can be exploited for developing inventions
aimed at preventing and/or reversing BPA-induced organ dysfunction and diseases.
Furthermore, if these findings could be extrapolated into an in vivo setting in humans, they
would suggest that GC treatment of respiratory disorders, such as asthma, might result in
GC resistance in cases where these disorders are caused by BPA exposure.
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DISCUSSION AND CONCLUSIONS
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5.1 Summary
The previous chapters describe a series of in vivo and in vitro experiments aimed to
elucidate the adverse effects of BPA on fetal lung development. In these experiments, I
examined the effects of prenatal exposure to BPA on fetal lung maturation, and defined the
molecular pathway through which BPA exerts its effects. I showed that exposure to
environmentally relevant doses of BPA severely impairs fetal lung maturation in the
mouse. This lung immaturity phenotype was characterized by defects in type I but not type
II epithelial cell differentiation. I also demonstrated that intervention with the synthetic
glucocorticoid dexamethasone rescues the lung immaturity phenotype. Finally, I
determined that BPA disrupts glucocorticoid signaling in lung epithelial cells through a
novel molecular pathway that involves ERβ-mediated activation of the key proinflammatory transcription factor NF-κB. Collectively, these findings demonstrate that
developmental exposure to environmentally relevant doses of BPA disrupts fetal lung
maturation through inhibition of the glucocorticoid signaling pathway. This study provides
evidence for a fetal origin of the previously reported BPA-induced lung dysfunction and
diseases in humans and in experimental animal models, thus supporting my hypothesis.
Furthermore, it identifies a novel molecular pathway of BPA actions involving the ERβmediated activation of NF-κB and subsequent inhibition of GR activity in lung epithelial
cells.

5.1.1 Doses of BPA Used in our in vivo Experiments
The BPA doses used in our in vivo experiments (5, 25, and 50 mg/kg diet; equivalent to 1,
5 and 10 mg BPA/kg body weight/day) were several orders of magnitude below the lowest
observable adverse effect level (LOAEL) for rodents (50 mg/kg/day), as established by the
U.S. Environmental Protection Agency1. Furthermore, one previous mouse study in which
the same BPA-containing food pellet (5 mg/kg diet; equivalent to 1 mg BPA/kg body
weight/day) was fed before and throughout pregnancy and lactation produced average
maternal plasma (unconjugated) BPA concentrations of 3.5 ng/mL2. Based on this study I
estimated a maximal maternal plasma BPA concentration of 20 ng/mL for the middle dose
(25 mg/kg diet; which is estimated to be maximal because pregnant mice were exposed for
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a total of 11 days in our study vs. 28 days in the previous study). Upon measurement, the
middle dose (25 mg/kg diet) produced average maternal plasma BPA concentrations of 1.7
ng/mL in our mouse model, which are at the lower end of the range (0.5–22.3 ng/mL)
reported in pregnant women in the U.S3. Although the precise reasons for our apparent
underestimation of plasma BPA concentrations are unclear, it is possible that BPA
degradation may be a contributing factor, as maternal plasma samples were stored at -80°C
for over 1 year before being analyzed for BPA concentrations. Nevertheless, even the
estimated maximal maternal BPA concentration of 20 ng/mL falls within the range of those
reported previously in pregnant women, indicating that the dosage used in the present study
is relevant to humans. Moreover, toxicokinetic studies that measure plasma levels of
unconjugated BPA following oral administration indicate that internal exposure to
unconjugated BPA in rodents, non-human primates, and humans are remarkably similar4.
This is important as it suggests that the mouse is a valid predictor of the consequences of
BPA exposure in primates, including humans, and highlights the potential impact of BPA
exposure during pregnancy on fetal lung development.

5.1.2 Prenatal Exposure to BPA Severely Impairs Fetal Lung
Maturation
Exposure to environmental chemicals during critical periods of development may produce
lifelong structural and functional alterations that become apparent only later in life.
Evidence is accumulating that disruption of lung development may be caused by some
environmental chemicals at environmentally relevant doses. Nonetheless, there is a paucity
of literature evaluating the impact of early-life exposure to environmental chemicals on
lung structure and function. In recent years, the adverse effects of BPA on human lung
function

and

associated

lung

diseases

has

become

increasingly recognized.

Epidemiological studies indicate that early life exposure to BPA is associated with
impaired lung function5 and the development of asthma6,7 and wheeze8,9 in children. In
addition, high serum levels of BPA have been linked to chronic obstructive pulmonary
disease (COPD)10. Animal studies show that perinatal exposure to BPA induces asthma in
adult mice11–14. Collectively, these findings demonstrate that early life exposure to BPA is
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detrimental to lung function, and suggest that BPA may alter fetal lung development, thus
potentially cause or contribute to lung diseases later in life.
In Chapter Three, a fetal origin for the BPA-induced lung diseases in adult life was
explored by examining the hypothesis that prenatal exposure to environmentally relevant
doses of BPA impairs fetal lung maturation in mice. These experiments demonstrate that
prenatal exposure to BPA severely impairs fetal lung maturation, as evidenced by the
diminished alveolar airspace and thickened alveolar septa, which are hallmarks of lung
immaturity. Concomitantly, the expression of the type I cell marker was dramatically
reduced in BPA-exposed fetal lungs.
This finding is supported by studies of other environmental chemicals that exert adverse
effects on the developing lungs. As summarized in Table 5.1, nitrofen15,16, 2,3,7,8Tetrachlorodibenzo-p-dioxin (TCDD)17, nicotine18,19, arsenic20, and di(2-ethylhexyl)
phthalate (DEHP)21,22 impair lung development by disrupting essential processes such as
branching morphogenesis, alveolarization, and cellular differentiation. Alarmingly,
epidemiologic studies evaluating lung function in individuals exposed prenatally to these
environmental chemicals report increased incidence of chronic lung dysfunctions and
diseases such as COPD, asthma, and lung cancer23, similar to the BPA-linked pathologies
mentioned above.
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Table 5.1. Environmental chemicals that can alter lung development by disrupting
essential processes such as branching morphogenesis, alveolarization, and cellular
differentiation that are essential for proper lung function after birth.
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Central signaling pathways involved in lung development are highly conserved24, thus any
disruptions in these pathways, including endogenous hormones, pharmaceuticals, and
environmental chemicals, may alter fetal lung development. Moreover, a variety of
transcription factors and nuclear receptors essential to these processes are susceptible to
interference during critical developmental stages. Knockout mouse models have been
instrumental in highlighting the importance of some signaling pathways, including
glucocorticoid receptor (GR)25,26, corticotrophin releasing hormone (CRH)27, critical signal
transduction proteins such as extracellular signal-regulated kinase 3 (Erk3)28,
differentiation genes of lung type I cells such as T1α29, and several transcription factors
that play key roles in development such as hypoxia-inducible factor 1α (HIF1α)30, HIF2α31, Sp332, and C/EBPα33. Mice deficient in these genes suffer from severe lung
immaturity that is reminiscent of the BPA-induced lung immaturity phenotype. Therefore,
it is likely that BPA disrupts fetal lung maturation by altering essential signaling pathways
in lung cells. Indeed, our data suggests that BPA functions likely by inhibiting the
glucocorticoid signaling pathway in lung cells.

5.1.3

BPA

Disrupts

Fetal

Lung

Maturation

by

Suppressing

Glucocorticoid Signaling
In Chapter Three, I showed that maternal administration of dexamethasone, which is a
common intervention in high risk pregnancies with threatened preterm delivery34, rescued
the lung immaturity phenotype and normalized type I cell differentiation. Given that the
BPA-induced lung immaturity phenotype closely resembles that of glucocorticoid deficient
(i.e. CRH-/- and GR-/-) mouse models25–27 and that maternal dexamethasone administration
rescues this condition, I hypothesized that BPA disrupts fetal lung maturation by
suppressing glucocorticoid signaling in fetal lungs. During the last stages of fetal lung
development, the withdrawal of lung liquid from the airways at birth is an important
process allowing the transition to air breathing35. Membrane channels that promote the
unidirectional movement of water, such as the epithelial sodium channel (ENaC), are
essential in fetal lungs, and these channels have been reported as targets for GC induction
in the lungs before birth36. Indeed, there is extensive evidence that ENaC expression and
function can be regulated by glucocorticoids, particularly in the lungs36–38. Several studies
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demonstrate that all three ENaC subunits (α, β and γ)

are rapidly induced by

dexamethasone in vitro in the type II epithelial A549 cell line36,37. In addition, GR-null
mice have reduced expression of ENaCγ in their lungs before birth26,38. Interestingly,
although ENaCγ expression is significantly reduced in the lung of GR-null mice,
expression of the ENaC α and β subunits is unaltered26,38. Another well-known GR-target
gene expressed in the lungs is glutathione peroxidase (GPX)39,40. GPX belongs to the
enzyme family with peroxidase activity whose main biological role is to protect tissue from
oxidative damage40. As shown in Chapter Three, the expression of ENaCγ and GPX was
significantly decreased in BPA-exposed fetal lungs. This suggests that the adverse effects
of BPA on fetal lung development are likely a result of inhibition of glucocorticoid
signaling. This inhibition can be achieved by either decreasing circulating levels of
corticosterone and/or antagonizing glucocorticoid actions in the fetal lungs. I found no
evidence to support the first possibility, as fetal plasma levels of corticosterone were not
altered at either E18.5, when the lung immaturity phenotype was observed, or E15.5, a
critical time point just before terminal lung differentiation. Collectively, these findings
suggest that BPA may suppress GC signaling which results in impaired fetal lung
maturation. A recent study using in vitro yeast bioassays found that BPA acts as a GR
antagonist, with a drug concentration causing 50% inhibition of 67 µM41. However, the
precise molecular mechanisms of this antagonistic relationship remained obscure.

5.1.4 BPA Alters the Expression of ENaCγ by Inhibiting the
Glucocorticoid Signaling Pathway
Next, I investigated the precise molecular mechanisms by which developmental exposure
to BPA inhibits glucocorticoid signaling. Since expression of ENaCγ, a well-known GR
target gene, was diminished in BPA-exposed fetal lungs, I tested the hypothesis that BPA
inhibits ENaCγ expression through repression of the glucocorticoid signaling pathway
using the A549 lung epithelial cell line as an in vitro model system. I first validated the
model by demonstrating a robust concentration-dependent suppression of ENaCγ
expression following BPA exposure, analogous to the in vivo results. I then showed that
both dexamethasone and siRNA-mediated knockdown of GR expression blocked the
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inhibitory effects of BPA on ENaCγ expression, suggesting that BPA repressed ENaCγ
expression via inhibition of GR activity.
To determine the precise molecular mechanism by which BPA represses GR activity, I
analyzed various aspects of the GR signaling pathway. Glucocorticoid binding to the
cytoplasmic GR results in its release from its chaperone proteins, and rapid nuclear
translocation42. Analysis of this pathway revealed that although BPA did not alter levels of
either HSP90 protein or GR protein, it reduced GR nuclear translocation. Taken together,
these results suggest that BPA inhibits GR activity by diminishing GR nuclear
translocation.
NF-κB is a pro-inflammatory transcription factor that plays a key role in amplifying
inflammatory and immune responses43. NF-κB is a heterodimeric protein composed of a
p50 and p65 subunit, with p65 primarily responsible for the transactivation function44.
Under unstimulated conditions, NF-κB resides in the cytoplasm in an inactive form due to
its association with its inhibitory protein (IκB-α). Following stimulation of cells, IκB-α
undergoes proteasomal degradation, allowing NF-κB to be released, and its rapid nuclear
translocation43,44. Recently, BPA has been shown to function as an inflammatory inducer
as it induces NF-κB expression and activation in various cell types 45–51. A mutual
antagonism exists between GR and NF-κB, whereby NF-κB represses GR and vice
versa44,52–54. Furthermore, this mutual antagonism is mediated through the p65 subunit of
NF-κB. Several mechanisms were identified to explain this antagonistic relationship. First,
the direct interaction between activated NF-kB and GR in the cytoplasm has been shown
to impair GR nuclear translocation55,56. Second, in the nucleus, NF-κB and GR compete
for co-activators and/or NF-κB can disturb the interaction of GR with its basal transcription
machinery thus inhibiting transcription of target genes44,54,57,58. Therefore, I determined
whether BPA stimulates NF-κB expression, which, in turn, would inhibit GR activity. I
found that treatment with BPA resulted in a significant increase in the expression and
activation of NF-κB (p65) while decreasing mRNA and protein expression of its inhibitory
protein, IκB-α. Moreover, inhibition of NF-κB activation by the specific inhibitor BAY 11702 abrogated the inhibitory effects of BPA on ENaCγ expression. Together, these findings
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suggest that BPA represses ENaCγ expression in A549 lung cells via induction of the NFκB signaling pathway, and consequent inhibition of GR activity.
The ability of estrogen to modulate inflammatory response via ERs (ERα and ERβ) has
been extensively established59,60. Furthermore, recent studies show that BPA can activate
the NF-κB pro-inflammatory pathway via ERs49,50. As a first step in examining if ER is
involved in mediating BPA-induced NF-κB expression and activation, A549 cells were
treated with BPA in the presence and absence of the ER antagonist ICI 182780. As shown
in Chapter Four, ICI 182780 blocked the effects of BPA on NF-κB (p65) and IκB-α,
suggesting that ERβ (although the ER antagonist does not discriminate the two nuclear
ERs, ERα is undetectable in the A549 cell line) mediates the effects of BPA on the NF-κB
signaling pathway. As induction of the NF-κB signaling pathway in BPA treated cells
inhibits GR activity, I reasoned that if BPA signals via ERβ to activate the NF-κB signaling,
the addition of ICI 182780 should block BPA inhibition of ENaCγ expression. Indeed,
ENaCγ expression was restored to control levels in the presence of the ER antagonist,
providing further support for the notion that BPA acts on ERβ to induce the NF-κB
signaling pathway, which in turn inhibits the GR activity.
Taken together, these findings suggest that BPA activates the pro-inflammatory NF-κB
signaling pathway via ERβ, leading to interference with the glucocorticoid signaling
pathway in lung cells. Glucocorticoids are the most commonly prescribed drugs for the
treatment of chronic inflammatory conditions of the respiratory tract61. If the present
findings could be extrapolated to the human, it is tempting to speculate that exposure to
BPA may contribute to glucocorticoid resistance/insensitivity, especially in patients with
chronic airway inflammation, such as asthma.
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5.2 Future Directions
I have provided evidence for a fetal origin for BPA-induced lung dysfunction and diseases
that are observed previously in adult life. Also, I have identified a novel molecular
mechanism by which BPA exerts its adverse effects on lung cells. Upon collectively
analyzing these findings, it is critical to recognize that there are a number of important
questions that remain to be resolved, some of which are discussed below.

5.2.1 The Effects of BPA on Primary Human Bronchial Epithelial
Cells (HBECs)
To determine whether the disruptive effects of BPA that were observed in the
adenocarcinomic human lung A549 cell line, can be replicated in a primary human
lung cell model.
Lung primary epithelial cells consist of mixed cell types, such as goblet cells, basal cells,
or ciliated epithelial cells, and are thus preferred as a good representative in vitro model to
capture the intrinsic properties of the in vivo lung. Well-established primary cell models
are useful in investigating properties of intact organs under normal or diseased conditions
as these cells are likely to be more physiologically relevant to in vivo organs, compared to
cancer-derived cell lines. However, the disadvantage of using primary cell cultures is these
cell types have a short life span and require specialized culture skills for expansion in
culture. Therefore, studies are usually conducted in immortalized cancer-derived cell lines
prior to experimenting in a primary cell model.
Exposure of the lung A549 cell line, an alveolar cell carcinoma-derived cell line that retains
some features of the type II alveolar epithelial cells, to nanomolar concentrations of BPA
resulted in the activation of the NF-kB pro-inflammatory pathway via ERβ, leading to
inhibition of the glucocorticoid signaling pathway. Given that the primary lung cell model
is more physiologically relevant to the human lung, it is imperative to determine whether
the observed effects of BPA are operating in primary cells. If BPA does indeed inhibit
glucocorticoid signaling in primary cells, this will have significant implications on human
exposure to BPA, especially in cases where BPA exposure occurs through inhalation62,63.
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More importantly, it is estimated that 30% of the normal healthy population is resistant to
treatment with glucocorticoids64. If BPA results in glucocorticoid resistance/insensitivity
in human lung cells, response to steroid treatment may become a major problem for many
people, especially those who suffer from a chronic inflammatory lung disease, such as
asthma.

5.2.2 To Determine Whether Aspects of the Signaling Pathway
Identified in vitro can be Observed in BPA-exposed Fetal Lungs
The identification of the molecular mechanisms triggered upon exposure to BPA
highlighted a potential pathway by which BPA may exert its adverse effects on the fetal
lungs. In Chapter Four, a novel molecular pathway was identified where BPA acts on ERβ
to activate the NF-κB signaling pathway, which in turn leads to diminished GR signaling
in lung epithelial cells. These findings suggest that BPA induces NF-κB activation through
binding to ERβ, which in turn inhibits GR activity. Future studies will be required to
determine whether this molecular pathway operates in vivo in fetal lungs following prenatal
exposure to BPA. These include: (1) determine whether exposure to BPA results in
decreased GR nuclear translocation in fetal lungs. (2) Measurement of p65 expression and
activation in fetal lungs at various time points (i.e. E15.5-E18.5). (3) Measurement of IκBα in fetal lungs at various time points (i.e. E15.5-E18.5). (4) Measurement of ERβ-target
gene expression in BPA-exposed fetal lungs, which will indicate whether the ERβ
signaling pathway is activated in fetal lungs following BPA exposure. The proposed
experiments will demonstrate whether the observed molecular pathway of BPA is evident
in fetal lungs following prenatal exposure to BPA. This will provide a potential pathway
by which BPA acts to disrupt fetal lung maturation, as well as provide critical insights into
the adverse effects of developmental exposure to BPA on fetal organ development.
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5.2.3 The Effects of Prenatal Exposure to BPA on Fetal Lung
Maturation in ERβ-null Mice
To determine whether ERβ mediates the effects of BPA on fetal lung maturation.
Several studies have demonstrated that estrogen is required for the formation and complete
development of alveoli, for the maintenance of existing alveoli, for lung homoeostasis, and
for alveolar regeneration in adult mice65–67. Interestingly, ERβ-null mice do not have a lung
immaturity phenotype at birth68. However, later in life, female mice begin to show signs of
decreased numbers of alveoli, suggesting deficient alveolar formation as well as evidence
of surfactant accumulation in their lungs65,69. The data presented in this thesis indicates that
BPA inhibits glucocorticoid signaling likely via ERβ-mediated induction of NF-κB. Since
ERβ-null mice do not have a lung immaturity phenotype at birth, these mice provide a
suitable model to examine whether ERβ is mediating the disruptive effects of BPA on fetal
lung maturation. I hypothesize that offspring of ERβ knockout mice will exhibit normal
lung development following prenatal exposure to BPA. If confirmed, this will provide
definitive evidence for a critical role of ERβ in mediating the effects of BPA on fetal lung
maturation.

5.2.4 To Determine the Short- and Long-term Consequences of
Prenatal Exposure to BPA
Considering that BPA-exposed newborn mice survive into adulthood, the immediate
(neonatal) and long-term (adulthood) consequences of BPA exposure during pregnancy
should be determined, particularly since chronic lung diseases such as asthma and COPD
have at least part of their origins in early life23,70,71. Based on the findings presented in this
thesis (i.e., fetal mice exposed to BPA via maternal diet display severe lung immaturity), and
given that epidemiological as well as animal studies suggest that early life exposure to BPA
is associated with impaired lung function and diseases later in life, it is important to
determine whether the severe lung immaturity observed in our BPA-exposed fetal mice
increases susceptibility to lung dysfunction and disease in both the neonatal period and during
adulthood. It is very likely that these developmental defects persist into adulthood, leading to
impaired lung function and diseases later in life. Moreover, the link between early life exposure
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to BPA and the susceptibility for airway disease in adult life has never been explored.
Examining the effects of prenatal BPA exposure on the adult lung and combining these
findings with our previous data documenting the disruptive effects of BPA on the fetal lung
will establish a direct link between fetal and adult lung disruptions resulting from prenatal
exposure to BPA.

5.3 Conclusions
Adverse events during early life can severely impact an individual’s long-term health.
Often, adverse events are unrecognized or only noted when developmental processes have
already been affected. Early life exposure to BPA is of concern for several reasons. First,
it affects the development of various fetal organs2,72–80. Second, it acts on multiple signaling
pathways involved in organ development81,82. Third, this disrupting chemical is highly
pervasive in our environment83,84. While the ban of BPA in baby bottles reduces postnatal
exposure, fetal exposure to BPA via maternal exposure remains. Both epidemiological and
animal studies clearly indicate that exposure to BPA, especially during fetal life, results in
lung dysfunction and diseases later in life. Thus, it is imperative to examine the adverse
effects of early life exposure to BPA on fetal lung development. The focus of this thesis
was to examine the hypothesis that the previously reported lung dysfunction and diseases
following BPA exposure may have a fetal origin. The first set of experiments described in
this thesis demonstrate that exposure to environmentally relevant doses of BPA during the
critical period of fetal development significantly impairs fetal lung maturation in mice. The
second set of experiments provides evidence that BPA inhibits GR activity via ERinduced activation of the NF-κB signaling pathway in lung epithelial cells. A schematic
diagram depicting the precise molecular pathway through which BPA represses ENaCγ
expression in lung epithelial cells is shown in Figure 5.1.
This model postulates unconjugated (free) BPA readily crossing the cell membrane,
binding to and activating the nuclear receptor ERβ. Once activated, ERβ translocates to the
nucleus where it inhibits IκB-α expression. With less IκB-α to sequester NF-κB in the
cytosol, more NF-κB is activated and translocates to the nucleus. As NF-κB is known to
antagonize GR in both the cytoplasm and the nucleus, it is postulated that GR nuclear
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translocation will significantly decrease, followed by decreased activation of GR-target
genes, such as ENaCγ. As a result, ENaCγ mRNA and protein expression, following
treatment with BPA, is significantly reduced. My present findings provide evidence for a
novel molecular pathway where BPA acts on ERβ to activate the NF-κB signaling pathway,
which in turn leads to reduced GR activity and consequent repression of ENaCγ expression
in lung cells. Clearly, this model is speculative and much work is required to provide
definitive evidence for this signaling pathway in mediating the effects of BPA on fetal lung
development. Nevertheless, the findings presented in this dissertation raise concerns about
the potentially deleterious effects of BPA on lung development in humans, especially given
that the BPA doses used in this study were within the range of exposure in humans. Our
hope is that this data, alongside epidemiological evidence of the increasing incidence of
lung diseases in human populations exposed to BPA during various developmental stages,
encourages regulatory agencies to ban this disruptive chemical from use in consumer
products.
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Figure 5.1: A schematic representation of the postulated molecular pathway by which
BPA represses ENaC expression in lung epithelial cells. In this model, BPA enters the
cell where it binds to ER, which in turn disassociates with its chaperone proteins, and
acquires the ability to translocate to the nucleus. Once inside the nucleus, ERβ binds to the
promoter of IκB-α and inhibits its transcription. With less IκB-α to sequester NF-κB in the
cytosol, more NF-κB is activated and translocates to the nucleus. As NF-κB is known to
antagonize GR in both the cytoplasm and the nucleus, it is postulated that GR nuclear
translocation will significantly decrease, followed by reduced expression of GR-target
genes, such as ENaCγ.
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